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"Whether men will be able to survive the changes of environment that their own skill has 
brought about is an open question. If the answer is the affirmative, it will be known some day; 
if not, not" - B. Russell (1955) 
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ABSTRACT  
Allergic diseases such as atopic eczema (AE) and asthma are chronic inflammatory disorders in 
which the regulation of the immune system is altered, in concert with disease-specific defects in 
target organs. Their inception requires gene-environment interactions but the molecular 
mechanisms contributing to the pathogenesis remain unclear. During the last decades there was a 
dramatic increase in the prevalence of allergic diseases worldwide and several environmental 
conditions have been implicated (e.g. pollution, changes in lifestyle, reduced biodiversity). These 
exposures are supposed to affect leukocyte function, possibly through epigenetic mechanisms, 
which are the ultimate connection between the cell and the environment. The overall aim of this 
thesis was to elucidate the DNA methylation signatures as an epigenetic marker associated to cell 
lineage (I)  and increasing age (IV) in primary blood leukocytes, and to compare DNA methylation 
(II, III) and miRNA expression (II) between healthy controls (HC) and patients with AE and 
asthma in connection with changes in mRNA expression.  
In study I, we found a particular DNA methylation landscape for each population of blood 
leukocytes that discriminates their lineage and that lymphoid cells are more methylated than 
myeloid cells. At the DNA methylation level, CD19
+
 B cells are the most different among all 
leukocytes. This study revealed that differences in cell composition may bias DNA methylation 
analyses conducted in DNA extracted from whole blood and provided a catalog of lineage-specific 
CpG sites. In study II, we compared DNA methylation and miRNA levels between AE patients 
and HC in four T cell populations isolated from peripheral blood. We discovered that circulating 
skin-homing memory CD4
+
CLA
+
 T cells isolated from AE patients have significant DNA 
methylation differences in 49 CpG sites and differential expression of 16 miRNAs compared to 
HC. Integrative data analyses with the differentially expressed mRNAs revealed that epigenetic 
signatures in AE patients are connected to the IL-10/IL-13 pathway. In study III, we analyzed the 
relation between genotype and epigenotype in the GSDMB/ORMDL3 asthma-susceptibility locus. 
We found significant differences in DNA methylation between children with controlled persistent 
asthma and HC. Methylation levels in three of these differentially methylated CpG sites correlate 
with the mRNA levels of ORMDL3. Causal inference tests revealed that both, single nucleotide 
polymorphisms and non-polymorphic CpG sites have independent effects on ORMDL3 mRNA 
expression. We also discovered that CD8
+ 
T cells contain a differentially methylated region in the 
5’UTR of ORMDL3 that is less methylated compared to other leukocyte subtypes, suggesting that 
methylation differences in ORMDL3 might promote lymphocyte driven inflammation. In study 
IV, we performed a pilot genome-wide DNA methylation analysis in whole blood, aiming to 
elucidate which genes had longitudinal changes in DNA methylation between 3 and 60 months 
after birth in healthy children. After filtering by lineage-CpG sites, we found 330 age-methylated 
CpG sites and 464 age-demethylated CpG sites that reflect the immunological window and are 
located on genes encoding for cytokines and chromatin remodelers.  
In summary, we discovered DNA methylation signatures in blood leukocytes associated to 
terminal differentiation and development, and demonstrated that compared to HC, patients 
suffering of AE and asthma have differences in DNA methylation and miRNA levels that might 
have functional impact on mRNA expression. The findings of this thesis provide new insights on 
genomic loci containing epigenetic differences between allergic patients and HC, that may be 
studied in the future as candidates for the development of preventive strategies, disease biomarkers 
or novel pharmacological therapies. 
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1 Introduction 
The deoxyribonucleic acid (DNA) contains the genetic information encoded by the 
sequential order of four nucleotides: adenine (A), guanine (G), thymidine (T) and 
cytosine (C). The human haploid genome has 3200 million nucleotides, but only 2 to 
3% of it contains information resulting into proteins and the rest encode for non-
coding ribonucleic acids (RNAs) and a huge amount of regulatory elements that have 
just started to become discovered
1
. The DNA sequence is 99.9% identical between 
humans, but mutations affecting only a single gene, are able to cause molecular 
defects leading to monogenic diseases like cystic fibrosis, hemophilia or sickle cell 
anemia. In complex traits such as atopic eczema (AE) and asthma, single nucleotide 
substitutions and other genetic variants may predispose to the phenotype and 
influence the response to treatments
2,3
. However, no genetic variant has been found 
necessary and sufficient to cause these complex diseases and typically, the heritable 
component does not follow Mendel’s law of inheritance. A body of research 
conducted during the last decades strongly indicates that the molecular mechanisms 
leading to complex inflammatory diseases involve many more elements than 
variations in the DNA sequence
4,5
. Then, the information encoded by the nucleotides 
is part of a more general code, coordinated by a complex network of chemical 
modifications that make this “book of life” functional. Parts of that network are the 
epigenetic modifications, which include DNA methylation, histone modifications 
and non-coding RNAs
6
. These modifications recruit molecular complexes that 
activate or silence genes and explain how the cells contained in the human body, 
having (almost) the same DNA sequence, differentiate in around 400 different cell 
types with diverse phenotypes and expressed genes
7
 (Figure 1).  
The term “epigenetics” was coined in 1942 by Conrad Hal Waddington8 and defined 
as “the branch of biology which studies the interactions of genes and their 
environment that bring the phenotype into being”. With marvelous anticipation he 
predicted that once a progenitor cell take a differentiation pathway, among several 
possibilities, it progress downhill in the epigenetic landscape until a differentiated 
stage
9
. It is known today that terminally differentiated cells can become progenitors 
by resetting the chromatin structure and the DNA methylation landscape, like the 
case in induced-pluripotent stem cells
10
, but the concept is still the same: epigenetic 
modifications acquired during differentiation remain as a cellular memory, which is 
heritable, and determine which genes are expressed, when they are expressed and 
where. The chemical modifications in the DNA bases or the chromatin, change gene 
expression and cell phenotype without changing the nucleotide sequence, and are 
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heritable by mitosis and/or meiosis. In recent years many new mechanisms like non-
coding RNAs (including miRNAs) are being considered as epigenetic modifications 
because they are involved in maintaining the cell memory and are heritable
11
. The 
epigenetic code make cells to remember their phenotype by keeping the activation of 
genes that must be active and repressing those that are not needed. At the time I write 
this thesis, there is a body of knowledge on how epigenetic modifications work under 
physiological conditions in a number of organisms. However, with the exception of 
cancer, very little is know about the role of epigenetic modifications in the 
pathogenesis of human complex diseases.  
 
Figure 1 
The human genome with almost the same DNA sequence in each cell results in millions of epigenomes 
with particular epigenetic landscapes according to cell lineage. Even within the same cell, the epigenome 
is remodeled by time, developmental stages and stimuli from the environment. 
 
There are two ways of influencing the pathogenesis of complex diseases: genetic 
mechanisms and the effects of the environment. In this scenario, the epigenetic 
modifications are an interphase between the two general mechanisms. Environmental 
factors from diet, pollutants, the microbiome, or pharmacological compounds, can 
induce epigenetic modifications that result in changes in the phenotype, sometimes of 
clinical relevance
12
. By their plasticity, and being reversible and heritable, the 
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epigenetic modifications might hold the clue to understand key molecular events 
leading to complex inflammatory diseases. In the case of allergic diseases such as AE 
or allergic asthma, there are reasons to believe that epigenetic modifications may be 
involved in their pathogenesis:  first, the discordance in the presence of the allergic 
phenotype between monozygotic twins
2
; second, differences in the age of disease-
onset and the spontaneous relapse over time in certain patients
13
; and third, the 
changes in disease prevalence that followed industrialization and other global 
trends
14
. Given the main role of inflammation in AE and asthma, the peripheral blood 
leukocytes are relevant target cells to study the epigenetic mechanisms contributing 
to disease predisposition or perpetuation. This PhD thesis aimed to identify DNA 
methylation signatures that occur under physiological conditions in peripheral blood 
leukocytes during terminal differentiation and childhood, as well as to identify 
epigenetic signatures associated to AE and asthma. This would improve our 
understanding of complex diseases, will help to detect objective markers of disease 
and facilitate the development of novel therapies.  
 
1.1 DNA methylation 
This epigenetic modification consists of the covalent binding of a methyl group 
(CH3) to DNA bases. The most studied form is the methylation of carbon 5 in the 
pyrimidine ring of cytosines (5-methylcytosine), when this nucleotide is followed by 
a guanine forming a CpG site (Figure 2a). The 5-methylcytosine was discovered in 
1948 by Rollin Hotchkiss by using paper chromatography
15
 , and it was not until 
1975 that the connection between methylation and gene expression was first 
proposed
16,17
. The methyl group does not affect the pairing of the 5-methylcytosine to 
the complementary strand, but it is positioned in the major groove of the DNA where 
it may affect gene expression by recruiting methyl binding proteins, and other 
complexes like the polycomb group (PcG), histone deacetylases (HDACs), histone 
methyltransferases, and chromatin remodelers. Altogether, they promote silent 
chromatin states and affect the accessibility of the underlying locus to the 
transcriptional machinery
18
. The interconnection between DNA methylation and 
other epigenetic layers like histone modifications, results in strong functional effects 
on mRNA expression. DNA methylation plays an essential role in the genome 
stability, chromatin condensation, X-chromosome dosage compensation (X-
inactivation), coordinated expression of imprinted genes and the regulation of cell-
specific gene expression during the different phases of the cell cycle
19
.  
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Figure 2  
a. The nucleotide sequence reads 5’ to 3’ and there are two CpG sites formed by a C followed by G; 
unmethylated cytosine is indicated by a white circle; methylated cytosine is indicated by a filled black 
circle. The methyl group (CH3) is taken by the DNA methyltransferases (DNMTs) from the S-adenosyl 
methionine (SAM) and added at the 5-carbon of cytosine. SAH: S-adenosyl homocysteine. 
b. The methylation status of any given CpG site at the single cell level. Each vertical sequence represents 
the paternal and maternal chromosome in 5’ to 3’ orientation. A CpG site is unmethylated (white circle) 
or methylated (filled black circle) if the status of the cytosine is equal in the maternal and paternal 
chromosomes. There are situations when a CpG site is methylated in just one chromosome but not in the 
other as in imprinting. The percentage of methylation is indicated assuming symmetrical methylation on 
the complementary strand (not shown). 
 
Since a single cell has two chromosomes from each parent, a given CpG site can be 
“unmethylated” if the methyl group is absent in the two parental strands or 
methylated if the methyl group is present in the two parental strands; under some 
conditions like imprinting, a CpG site can be methylated in just one parental 
chromosome (Figure 2b). Hemimethylation occurs if one strand is methylated but the 
complementary is not, and probably reflects post-replication lag in the maintenance 
of DNA methylation or de novo events. DNA methylation is one of the most studied 
epigenetic modifications by the strategic advantage that it can be robustly measured 
by a number of current methodologies
20
, and by its stability under clinical collection 
conditions and storage. The DNA methylation measurements can be expressed as a 
quantitative value (e.g. percentage, Illumina β-value, M-value), that reflects the 
average methylation level of a specific CpG site in all the cells contained in any 
given sample.  
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It is estimated that there are 28 million CpG sites in the human genome and ~80% of 
them are methylated. More than one-third of the methylated CpG sites are located in 
retrotransposons and regions with highly repetitive DNA like Alu sequences, long 
interspersed nucleotide elements (LINE), short interspersed nucleotide elements 
(SINE) and centromeres. DNA methylation in these repetitive sequences is essential 
in maintaining genome stability
21,22
. Besides, there are short stretches of DNA 
sequence with a high content of CpG sites, called CpG islands (CGI) and defined as 
intervals of 200 to 500 base pairs (bp) with a CG percentage above 50% and an 
observed/expected CG ratio above 60%
23
. The CGI indicate the promoters of more 
than 50% of all human genes. Most CGI are unmethylated, even when the gene is 
transcriptionally inactive
24
. Aberrant methylation of promoter-associated CGI is 
typically observed in tumors. The CGI located inside the genes (intragenic) or in 
“apparently” non coding regions (intergenic) are usually methylated. There is 
evidence that they are biologically relevant and can be methylated in a tissue-specific 
manner
25
. The 2 kb regions immediately flanking the upstream and downstream of a 
CGI are called CGI shores (Figure 3a). They have lower content of CpG sites 
compared to a CGI. However, it has been found that CGI shores contain the highest 
variation in DNA methylation between cell types and also between healthy and 
cancer cells
26
. The regions of 2-4 kB immediately adjacent to the CGI shore are 
called CGI shelves. The rest is annotated as non-CGI related.  
Methylated DNA in the proximity of transcriptional start sites (TSS) and in the 
surrounding of the first exon has been historically associated with suppression of 
gene expression
27
. However, DNA methylation levels and mRNA levels do not 
always follow an inverse relationship. Indeed, the location of the CpG sites within 
the gene structure have been found to play a crucial role in determining if a DNA 
methylation mark will lead to up-regulation or down-regulation of gene expression. 
The CpG sites mapped to coding genes can occur in promoters, untranslated regions 
(UTR), introns or exons (Figure 3b). In general, CpG sites located in gene bodies are 
strongly associated to increased gene expression in dividing cells
28,29
 while if located 
in a promoter, DNA methylation can lead to either up-regulation or down-regulation 
of gene expression. DNA methylation in the gene body is very intriguing because 
this feature is conserved in evolution and seems to regulate the mRNA level of genes 
in the mid-expression range. Many tissue-specific differentially methylated regions 
have been found in the gene bodies, including intragenic CGIs
30
. Two functions have 
been found to be related with gene body methylation: regulation of alternative 
splicing and the prevention of transcriptional initiation in the gene body
31
.   
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Figure 3 
a. Location of CpG island (CGI), CGI shores and CGI shelves in relation to the transcriptional start site 
(TSS). CGI are usually CG-rich regions and their CpG sites are unmethylated (white lollipops). CpG 
island shores and shelves have less CpG sites compared to CGI but they are more frequently related to 
specific DNA methylation patterns depending on tissue or disease. CGI shores have been found to have 
strong effects on mRNA expression. Methylated CpG sites are indicated by black lollipops.   
b. Location of CpG sites according to gene structure. Gene body is defined as the region immediately 
after the first exon. Methylation in intragenic CpG islands (iCGI) correlates with silencing of the 
associated gene32. 
 
1.1.1 The DNA methylation machinery 
From early developmental stages through childhood and senescence the DNA 
methylation marks are written and erased, copied and edited. Some regions are very 
dynamic and can be modified by age or environmental exposures
33
. The DNA 
methylation machinery is responsible for keeping the fidelity of the code after each 
cell division or to modify it if needed. In eukaryotic cells the methyl groups are 
added after replication by DNA methyltransferases (DNMTs), a family of enzymes 
that catalyzes the transfer of a methyl group from S-adenyl methionine (SAM) to 
cytosines. DNMT1 is responsible for copying the methylation pattern from the 
parental strand to the daughter strand during mitosis, and is considered the 
maintenance methyltransferase (Figure 4). This enzyme is located in the replication 
fork and has preference by the hemimethylated DNA
34
. The DNA methyltransferases 
DNMT3A and DNMT3B provide de novo methylation during embryogenesis or in 
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response to environmental stimuli
35
. DNMT3A is expressed ubiquitously, while 
DNMT3B is poorly expressed by the majority of differentiated tissues with the 
exception of the thyroid, testes, and bone marrow
36
. Studies in knockout mice 
support that Dnmt3b is required during early development, whereas Dnmt3a is 
required for normal cellular differentiation
37
. The DNMT3L is homologous to 
DNMT3A and DNMT3B, but lacks the catalytic domain of DNMTs. Nevertheless, 
this enzyme stimulates the methyltransferase activity of DNMT3A and B
38
 and it is 
required to establish maternal and paternal genomic imprints. DNMT3L is mainly 
expressed during early development and is restricted to germ cells and thymus in 
adulthood
39
. Targeted de novo DNA methylation may occur mediated by 
transcription factors (TFs) that either recruit DNMT3A or bind to the DNA sequence 
and protect the underlying locus from de novo methylation. CGI appear to be 
protected from methylation by TF binding, and when the TF binding sites are 
mutated the CGI are unable to retain their unmethylated state. The changes in the 
expression of TFs that occur during cell differentiation or aging may expose CpG 
sites to be targeted by the DNMTs machinery
40
. 
The removal of methyl groups (demethylation) also plays an essential role for cell 
biology and can occur by passive or active mechanisms. Passive demethylation 
results of decreased DNMT1 activity during cell replication, which renders the 
daughter strands unmethylated. Therefore, a CpG site initially methylated is 
replicated as unmethylated during successive divisions (Figure 4). Active 
demethylation requires several steps of enzymatic reactions that convert the 5-
methylcytosine to cytosine. One step involve the addition of a hydroxyl group by ten-
eleven translocator proteins (TET) that convert 5-methylcytosine to 5-hydroxi-
methylcytosine (5hmC)
41
. The 5hmC can be further oxidized by TET proteins to 5-
formyl-cytosine and 5-carboxyl-cytosine. Alternatively, 5-methylcytosine can be 
deaminated by the activation induced deaminase (AID/APOBEC) to form 5-
hydroxymethyluracil. Thereafter the thymine DNA glycosylase (TDG) and base 
excision repair (BER) glycosylases replace these intermediates by cytosine and 
complete the DNA demethylation
42
.  
Right after fertilization the DNA methylation marks are globally deleted in the 
zygote (with some exceptions), which result in a hypomethylated genome with 
totipotent capacity to generate any cell type in the preimplantation embryo
43
. The 
demethylation of the paternal genome is an active process that removes DNA 
methylation marks within hours after fertilization while the maternal genome is 
passively demethylated during cleavages up to the blastocyst stage
44,45
. In the 
gastrulating embryo the DNA methylation marks are replenished by de novo 
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methylation. Thereafter, DNA methylation participates in defining the epigenetic 
landscape of each cell lineage (as n methylomes, Figure 4), guiding the 
differentiation processes, reinforcing cell commitments and preventing regression to 
undifferentiated states. A second phase of re-programming occurs in the primordial 
germ cells during embryogenesis where DNA methylation patterns are erased in 
coding genes and some repetitive elements
46
. After birth, some loci exhibit changes 
in DNA methylation in differentiated cells that affect single CpG sites or regions
33
. 
 
 
 
Figure 4  
DNA methylation levels are in constant change during development, in response to physiological 
processes and the environment. Filled black circles indicate methyl groups; gray circles indicate 
chemical intermediates of 5-methylcytosine; lightning indicate TET proteins; pie symbol indicate 
DNMTs; the daughter strand after DNA replication is presented in gray. 
 
The DNA methylation marks are read by at least three families of proteins: the 
methyl-CpG-binding domain (MBD) proteins
47
, the ubiquitin-like, containing PHD 
and RING finger domain (UHRF) proteins and zinc finger proteins. MBD proteins 
include MeCP2 along with MBD1, MBD2, MBD3 and MBD4. This family mediates 
transcriptional repression by recruiting chromatin remodeling complexes and histone 
deacetylases (HDAC)
48
. MBD4 is a repairing enzyme that preferentially recognizes 
  21 
deaminated 5-methycytosines. The UHRF protein family (particularly UHRF1) 
actually recognizes hemimethylated DNA during DNA replication and recruits 
DNMT1 to catalyze the methyl-transference reaction
49,50
. The zinc finger proteins 
bind to methylated DNA by a zinc-finger domain and include Kaiso, ZBTB4, and 
ZBTB38
51
. They can bind single methylated CpG sites or two consecutively 
methylated CpG sites and repress transcription in a DNA methylation-dependent 
manner. Overall, methyl binding proteins provide the strongest link between DNA 
methylation and histone modifications, the combinations involved can modify gene 
expression and maintain the methylation code
52
.  
 
1.1.2 DNA methylation and chromatin remodeling 
 
The DNA methylation patterns contribute to regulate gene expression and thereby 
cell-specific functions. However, since the DNA is wrapped in high order structures 
like nucleosomes and chromatin, a gene can only be transcribed if the chromatin 
structure changes to allow transcription
53
. The nucleosome is the functional unit of 
the chromatin, and consists of 147 bp wrapped in an octamer of globular proteins 
called histones (one H3 H4 tetramer and two H2A-H2B dimers). Those are positively 
charged and have a great affinity for the DNA which is negatively charged. The 
aminoacids of the histone tails are targets of post-translational modifications (e.g., 
acetylation, methylation, ubiquitination, phosphorylation, sumoylation) that enable or 
prevent the access of regulatory proteins and the transcriptional machinery to the 
DNA
54
. Approximately 60 aminoacid residues can be modified in core histones but 
only a small number of modifications have been associated to changes in 
transcriptional activity
55
. In most cases histone acetylation and phosphorylation lead 
to gene activation whereas histone methylation, desacetylation, and ubiquitination 
lead to gene inactivation. Histone modifications are added and removed by a 
newtwok of enzymes that work in coordination with chromatin remodelers
56
. Histone 
acetylation is mediated by lysine acetyltransferases (KAT) which transfer an acetyl 
group from acetyl-CoA to an -amino groups in lysines. Removal of acetyl groups is 
catalized by histone deacetylases (HDAC). Moreover, histones can be mono-, di- or 
trimethylated at lysine residues by lysine methyltransferases (KMTs), which transfer 
a methyl group from SAM to -amino groups in lysines. The removal of methyl 
groups from histones is catalyzed by lysine demethylases (KDM). The lysine-
specific demethylase 1 (LSD1 or KDM1A) removes mono- and di- methylation and 
the jumonji demethylase family is able to remove trymethylation
57,58
. The 
methylation of lysines can lead to activation or repression depending on the residue 
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that is modified, for instance H3K4me3 is correlated to active gene expression while 
H3K9me2/3 is a repressive mark. Histone modifications can also recrutit DNMT3A 
which de novo methylate the CpG sites wrapped in that histone
59
.  
 
The changes in the structure of chromatin are mediated by ATP-driven molecular 
machines called chromatin remodelers (CR)
60
. They translocate the nucleosomes or 
evict them from the DNA, thereby affecting the accessibility of the transcriptional 
and the repairing machineries to the template DNA. The catalityc subunits associate 
to non-catalityc ones in complexes. CR are divided in four main families based on 
the sequence of their ATPase subunit: switching defective/sucrose nonfermenting 
(SWI/SNF), imitation switch (ISWI), CHD (chromo domain helicase DNA-binding) 
and inositol requiring 80 (INO80). The combined effects of CR, histone modifiying 
enzymes, chaperones and DNMTs are transient and very dynamic. The cell 
phenotype and/or cell-specific gene-expression are the outcomes. By the time that a 
sample of differentiated cells is assessed by current methodologies many of these 
molecular complexes (and their potential variations under disease traits) can have 
vanished. In this scenary, DNA methylation marks at single nucleotide resolution or 
in differentially methylated regions, may represent a vestige of other molecular 
events that underwent in a locus. This concept may be important to bear in mind 
when interpreting the effect sizes of comparing DNA methylation levels. 
 
1.1.3 The polycomb group (PcG) 
The polycomb group is a family of transcription regulatory proteins that play a 
crucial role in developmental processes and cell differentiation by creating and 
maintaining repressive chromatin environments. PcG proteins associate in molecular 
complexes that allow them to regulate the transcription of a great number of genes 
from the early embryogenesis, through infancy and adulthood. The polycomb was 
first described in Drosophila as repressors of the homeotic genes (Hox) in the 
bithorax complex
61
. The PcG mediate gene silencing by remodeling the chromatin 
and are classified as epigenetic regulatory proteins. PcG proteins form two major 
polycomb repressive complexes: PRC1 and PRC2 that are compositionally and 
functionally conserved in flies and humans
62,63
. In humans, PRC1 is formed by CBXs 
(polycomb homolog), PHC1,2, and 3 (polyhomeotic homologs), Ring1a and Ring1b 
(as dRING homologs) and, BMI1 and six minor others (as posterior sex combs 
homologs). The human PRC2 includes EZH1/2 (as enhancer of zeste), SUZ12 (as 
supresor of zeste 12), embryonic ectoderm development (EED) and RbBP4
64
 (Figure 
5). A known function of PcG proteins is the catalysis of H3K27. First PRC2 binds to 
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chromatin and the catalytic subunit EZH2 trimethylates H3K27, then H3K27me3 is 
recognized by the CBX components of PRC1, the ligases RING1/2 
monoubiquitinates H2A on K119 resulting in chromatin compation
65
. 
At present, it is still unclear how the PRC2 is directed to its target promoters in 
mammals, but some studies in mouse stem cells have shown the participation of 
proteins like JARID2
66
 and polycomb like proteins (Pcl)
67
. Furthermore, subunits of 
the PcG directly interact with the DNMTs and play a crucial role in regulating 
genome-wide and locus-specific methylation patterns. For instance EZH2 serves as a 
scaffold and direct link between methylated histones and the DNA methylation 
machinery at repressed promoters. The binding of DNMTs to repressed genes 
depends on the presence of EZH2
68
. Most of the knowledge currently available on 
PcG proteins is related to their functions in regulating stem cell activity, 
developmental processes and cancer
69
. There are many other family members of the 
PcG and associated molecules which biological functions and interactions are less 
known. A summary of the human polycomb complexes and some of their known 
interactors are presented in Figure 5. 
 
 
 
Figure 5 
The components of the human polycomb group (PcG). DNA is represented by a purple line turning 
around histone cores (lilac). CpG sites are denoted by white circles (unmethylated) and filled black 
circles (methylated). Transcription factors (TF), Jumonji AT rich interactive domain 2 (JARID2) and 
non-coding RNAs bind to CpG rich regions and recruit the PRC2 (blue) and the canonical and non-
canonical versions of the PRC1 (pink). PHF1: PHD finger protein 1; KDM2: Lysine (K)-specific 
demethylase 2. 
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1.1.4 5-methylcytosine as an alternative allele  
An additional level of complexity is added by single nucleotide polymorphisms 
(SNPs) that coincide with CpG sites and influence in cis the levels of DNA 
methylation in other CpG sites located in their surroundings. DNA methylation has 
been found as a heritable continuous quantitative trait in several tissues including 
brain and peripheral blood leukocytes
70
. Some of the genetically regulated DNA 
methylation is directly connected with variation in gene expression
71
. The majority of 
CpG sites are non-polymorphic, but 5-methylcytosine is prone to mutagenic events 
that cause C to T transitions. When a SNP coincides with a CpG site (for example a 
C is changed to T), the CpG site is removed and there is no possibility of methylation 
for the carriers of the T allele (TpG) (Figure 6a). Alternatively, if the polymorphic 
variant is a C or a G, they can create a CpG site. As mentioned above, a methylated 
cytosine can bind nuclear proteins that do not bind to unmethylated cytosines, and 
therefore can modify the binding of TF or recruit other nuclear molecules
72,73
 (Figure 
6b). This setting configures the 5-methylcytosine as the third allele.  
 
 
Figure 6 
a. A CpG-site SNP. The cytosine has the possibility to be methylated (filled black circle) as the 3rd allele.  
b. Electrophoretic mobility shift assay comparing nuclear protein binding between probes with allele T, 
allele C or the methylated allele C (CM), modified from Reinius et al.72  
c. Schematic model of a CpG-site SNP affecting the DNA methylation levels of other non-polymorphic 
CpG sites in its surroundings (methQTL) by the differential recruitment of nuclear proteins by the 
polymorphic allele; white lollipops indicate unmethylated CpG sites; black filled lollipops indicate 
methylated CpG sites; eQTL: expression quantitative trait locus. 
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Alternatively, SNPs can influence regional DNA methylation levels in other CpG 
sites located in their surrounding
74
 (Figure 6c). These CpG site-SNPs are quantitative 
trait locus for methylation (methQTLs). Studies have shown that the cis methQTL 
effect occurs in a range of 45 bp from the site in question and is most likely in CpG 
sites located outside the CGI
75
, although effect-windows of up to 1 Mb have been 
described
70
. The association between alleles and regional DNA methylation levels 
highlight the fact that the underlying DNA sequence (even if it is not directly 
modified in terms of the nucleotides), can definitively influence the epigenetic 
modifications placed on it (in particular allele-specific DNA methylation
76
). It has 
been estimated that about 20% of the differences in DNA methylation levels between 
individuals has a genetic association
77
.  
 
1.1.5 DNA methylation and leukocyte differentiation 
The process of cellular differentiation is the hallmark of epigenetic regulation and 
indeed, epigenetic changes mediate and maintain the fate that multipotent 
hematopoietic progenitors will follow in a differentiation pathway towards 
developing into a lymphocyte or a neutrophil. Studies on the epigenetic marks 
(including CpG sites) that may categorize cell populations according to their lineage 
have been under extensive research for more than two decades. A comprehensive 
methylome map of hematopoietic progenitors revealed that DNA methylation 
correlated with gene expression and is directly implicated in lineage choice
78
. Indeed, 
alterations in the DNA methylation patterns of hematopoietic progenitors have been 
found to cause many hematological malignancies
79,80
. Studies in mice and human 
cells have shown that DNA methylation increases with the commitment to the 
lymphoid lineage and decreases with the myeloid differentiation program
78
. The 
analysis of candidate genes has identified some CpG sites and genes that can be used 
to predict lineage commitment in human leukocytes
81-83
. However, little is known 
about the genomewide DNA methylation landscape of terminally differentiated 
leukocytes that circulate in peripheral blood.  
In a healthy adult about 10
12
 new blood cells are produced every day by the bone 
marrow. The presence of colony stimulating factors and cytokine signals in the 
microenvironment, induce epigenetic changes that determine the paths that the 
hematopoietic progenitors will follow until a differentiated state and confer their cell-
identify and cell-specific functions. Lymphoid cells originate from the common 
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lymphoid progenitor and include T cells, B cells, natural killer cells (NK)
84
 and other 
populations of innate lymphoid cells
85
. Myeloid cells originate from the common 
myeloid progenitor (granulocyte-macrophage lineage) and include granulocytes 
(neutrophils, eosinophils and basophils), monocyte/macrophages and mast cells. The 
dendritic cells (DC) originate from both, lymphoid and myeloid progenitors, and are 
found in very small proportions in blood while they are in transit to the tissues as 
plasmacytoid DCs (CD303
+
), or myeloid DCs (CD1c
+
 and CD141
+
). Since lymphoid 
and myeloid cells have profound differences in their DNA methylation levels, the 
estimates of DNA methylation obtained from whole blood can be affected by cell 
heterogeneity, especially if the targeted CpG sites coincide to those implicated in cell 
linage. By the time I started my thesis, this limitation was not widely recognized. 
Several studies were already published studying methylation in DNA in samples 
obtained from whole blood
86
, and many research groups around the world were in the 
transition to evaluate the DNA samples left from the genome-wide association 
studies (GWAS) era with the arrays for DNA methylation-wide association studies. 
Blood contains a complex mixture of leukocytes that account for 0.1 to 0.2% of all 
components and are divided in lymphocytes and myelocytes; the rest are erythrocytes 
(93-96%) and platelets (4-7%). Peripheral blood leukocytes are distributed in 
different proportions that vary depending on the individual, age, and the presence of 
infections or inflammatory conditions (Table 1). The immuno-phenotype of the 
leukocytes can be identified by flow cytometry with the use of cell surface markers 
that are characteristic of each cell type. 
T lymphocytes are distinguished from B cells and NK cells by the presence of the T 
cell receptor (TCR) on their cell surface. They are divided in T helper cells, which 
express the CD4
 
glycoprotein (CD4
+
 cells) and T cytotoxic cells expressing the CD8
 
glycoprotein (CD8
+
), and are present in peripheral blood in a rough 2:1 ratio
87
. Both 
subsets of T cells can be divided in conventional naïve if they express the CD45RA
+
 
marker, or antigen-experienced memory T cells if they express CD45RO
+
. The latter 
are antigen specific cells that originate from naïve T cells upon antigen stimulation 
and can live for long periods of time as central memory T cells or effector memory T 
cells. Other T cell populations in minor proportions in blood include regulatory T 
cells (inducible and natural), natural killer T (NKT) cells, scarce gamma delta T cells 
and CD4
+
CD8
+
 T cells. It is worth to keep in mind that even within the same 
population (e.g. CD4
+
 T cells), the circulating T cells correspond to a mixture of 
diverse developmental stages, activation status and imprinted cytokine patterns (e.g. 
Th1, Th2, Th17, Th9, induced T regs).  
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The CD19
+
 lymphocytes found in peripheral blood correspond to sub-populations of 
B cells that have differentiated from the early B cell precursor into mature B 
lymphocytes and emigrated from the bone marrow to the secondary lymphoid organs 
and tissues. Peripheral blood B cells can be grouped in immature/transitional (5.4%), 
naïve (64%), memory B-lymphocytes (31%), and plasmablasts (2.1%). Based on the 
differential expression of immunoglobulin heavy chains, the B cells can be further 
divided in IgM
+
, IgD
+
, IgG
+
, IgA
+
 and very scarce IgE
+
 cells.  
The natural killer cells (NK) play critical roles in innate immunity, shape adaptive 
immune responses and even participate as immune-regulatory cells. There are at least 
five subtypes of NK cells in human peripheral blood based on the expression of 
CD56 and CD16. The CD56
dim
CD16
bright
 subset represents 90% of circulating NK 
cells; they contain the inhibitory killer cell receptors (KIR), have strong cytotoxic 
activity and high concentration of perforins and granzymes
88
. A maximum of 10% of 
all circulating NK cells are CD56
bright
 in combination with CD16
-
 or CD16
dim
. 
Table 1. Frequencies of leukocytes in human peripheral blood (adults) 
 
frequency 
(x106 cells/mL) 
% of circulating 
leukocytes 
Conditions 
lymphocytes 1.1-3.5 14-47  
T cells  0.54-1.79 7-24  viral infections 
CD4+ T 0.30-1.50 4-20  
naïve CD4+ T 0.08-0.76 1-10  
memory CD4+ T 0.25-0.81 3-11  
regulatory CD4+CD25+ 0.007-0.05 0.1-0.7  
CD8+ T 0.14-0.82 2-11  
naïve CD8+ T 0.03-0.21 0.4-2.6  
memory CD8+ T - 1-7  
B cells 0.07-0.53 1-7 
infectious mononucleosis 
(EBV) 
naïve B cells 0.05-0.37 0.7-4.9  
memory B cells - 0.2-1.7  
NK cells 0.08-0.43 1-6  
myelocytes    
monocytes 0.20-0.90 2-12 SLE, RA 
granulocytes 2.13-6.35 35-80 bacterial infections 
neutrophils 2.09-5.97 30-80 bacterial infections COPD 
eosinophils 0.03-0.30 0-7 
allergy, asthma, AE 
helminthic infection 
basophils 0.01-0.08 0-2  
COPD: chronic obstructive pulmonary disease; DC: dendritic cells; EBV: Epstein-Barr virus; NK: 
natural killer; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus. Myeloid DC represent 0.3 
to 0.9% of all leukocytes; plasmacytoid DC represent 0.2 to 0.6% of all leukocytes. The values 
presented in this table were obtained from stemcelltechnologies™. 
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Regarding myeloid cells, human monocytes circulate few days in blood before they 
migrate to tissues and develop into different types of macrophages. Based on the 
expression of the cell surface marker CD14, they are divided into classical 
(CD14
++
CD16
-
), intermediate (CD14
++
CD16
+
) and non-classical (CD14
+
CD16
++
) 
monocytes
89
. It is worth to mention that monocytes have a non-segmented nucleus 
and by their density they isolate with the peripheral blood mononuclear cell fraction 
(PBMC).  
The peripheral blood granulocytes include the neutrophils, eosinophils and basophils. 
The neutrophils are the most abundant cell population in blood and the daily 
production can reach up to 2x10
11
 cells. Once released from the bone marrow as 
polymorphonuclear (segmented) cells, they can survive up to 4 to 5 days. They have 
low transcriptional activity but store several pro-inflammatory molecules and 
enzymes in their granules. Neutrophils are the first line of defense against bacterial 
infections by acting as phagocytes and creating extracellular traps (NETs)
90
.  
Eosinophils are innate immune cells with lobulated nucleus that have a life span of 2 
to 5 days. Their cytoplasmic vesicles are loaded with cytotoxic enzymes that are 
crucial in the defense to parasites; however, eosinophilia is a common feature of 
allergic diseases induced by the production of IL-5
91
. Basophils are the least common 
of the granulocytes and account for less than 1 percent of all leukocytes. They 
express the FcRI on the surface and their activation leads to granule exocytosis. 
Basophils release heparin, histamine and elastase and are potent producers of IL-4 
and IL-13. They share many features with mast cells (present in tissues) but the latter 
constitute a different cell lineage
91
.   
1.1.6 DNA methylation and human diseases 
Mutations in genes encoding DNMTs and other enzymes of the human methylation 
machinery usually result in large-scale methylation defects, and if the conceptus is 
viable, into clinical syndromes like immunodeficiency centromeric instability and 
facial abnormalities (DNMT3B, OMIM#242860); Rett syndrome (MeCP2, 
OMIM#312750); and hematological malignancies (DNMT3A, OMIM# 602769). 
There are other conditions in which the DNA methylation landscape is affected by 
epimutations that lead to imprinting disorders such as the Beckwith-Wiedemann 
syndrome, Silver-Russell syndrome, Prader-Willi and Angelman syndrome among 
others
92
. DNA methylation defects have been also associated to human diseases with 
repeat-instability involving folate-sensitive fragile sites (i.e. Fragile-X syndrome) and 
methylatable CGG repeats
93
. One of the best demonstrated effects of altered DNA 
methylation in human diseases is the development of malignancies
94
, with genome-
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wide hypomethylation and locus-specific hypermethylation of tumor-suppressor 
genes as hallmarks. Hypomethylation usually occurs in repetitive regions and 
retrotransposons resulting in genomic instability, aberrant activation of oncogenes 
and loss of imprinting. Gene-specific methylation usually occurs in the promoter 
regions of tumor suppressor genes
95
. For the interested reader, the database Pubmeth 
(http://www.pubmeth.org/) contains curated information on the genes with altered 
DNA methylation in diverse types of cancer. Research on the field of schizophrenia, 
bipolar disorder, autism spectrum disorders, anxiety and depression suggested that 
subtle DNA methylation changes are involved in the pathogenesis of complex 
traits
96
.  
Regarding complex inflammatory diseases, differences in DNA methylation has been 
found in systemic lupus erythematosus (SLE); for instance, the genomes of the T 
cells in SLE patients have global hypomethylation and the levels of DNMT1 are 
reduced
97
. Differences in DNA methylation have been described for Type I 
diabetes
98
. However, the differences in methylation that have been detected between 
patients affected by complex inflammatory diseases and controls are typically very 
small. Some studies applied cut-offs of a mean difference in DNA methylation levels 
of 5% or 10% between affected and non-affected groups at single nucleotide 
resolution, but the functional outcomes of these small DNA methylation changes are 
still largely unknown. 
 
1.2 microRNAs 
In the last years new empirical evidence in plants, fungi and metazoans revealed that 
non-coding RNAs (ncRNAs) play a role as epigenetic regulators
11,99,100
. Depending 
on their length in nucleotides (nt) these molecules can be grouped in small non-
coding RNAs (<30 nt) and long non-coding RNAs (>200 nt). Both groups have 
shown to have a role in regulating chromatin structure, heterochromatin formation, 
histone modifications, DNA methylation targeting and gene silencing. The group of 
small ncRNAs contains the miRNAs, short interfering RNAs and the piwi-
interacting RNAs. There is still controversy whether those molecules can be regarded 
as epigenetic mechanisms, but indeed they modify gene expression without affecting 
the DNA sequence and are heritable
11,101
. In the case of miRNAs, experiments in 
plants have shown that miR-165 and miR-166 are required for the methylation at the 
PHABULOSA (PHB) gene in Arabidopsis. They interact with the newly processed 
PHB mRNA and alter the chromatin in the PHB DNA template
102
. Other studies 
have shown that miRNAs control the expression of epigenetic regulators by directly 
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targeting DNA methyltransferases, histone deacetylases and PcG genes
103
.  A curated 
list of examples how miRNAs regulate epigenetic modifications can be found in the 
EpiMiR database
104
. The most studied ncRNAs are the miRNAs and in the following 
lines I will refer to their biology. 
miRNAs are small non-coding RNA molecules (~22 nucleotides, single-stranded) 
that regulate the translation of protein coding genes. This mechanism of post-
transcriptional regulation implicates complementary base-pairing between the 
miRNA and the target RNA molecule. In animals the interaction between the 
miRNA and the mRNA target require as few as 8 nucleotides (the seed region) and 
usually the complementary site is located on the 3’UTR of the target mRNA. Any 
given miRNA can have hundreds of mRNA targets, and a mRNA transcript can be 
targeted by several miRNAs. It has been estimated that each conserved vertebrate 
miRNA can have ~400 targets
105,106
. The nomenclature of miRNAs is simply 
sequential, lettered suffixes denote closely related mature sequences (e.g.  miR-18a 
and miR-18b). When two miRNA sequences (22 nt) originate from the opposite arms 
of the same precursor but it is not possible to determine which is the predominant 
one, the suffix 5p (from the 5’ arm) and 3p (from the 3’arm) are used. 
1.2.1 Generation of miRNAs 
miRNA genes are encoded in the nuclear DNA and represent ~4% of the human 
genes. They are encoded in different parts of the genome either in dedicated miRNA 
genes, usually found in intergenic regions, or by sequences embedded in the 
antisense strand of a host mRNA coding gene. About 40% of all miRNAs are 
produced in polycistronic units with multiple loops. The miRNA genes as any other 
gene are subject to epigenetic regulation by DNA methylation and histone 
modifications. The miRNA genes are transcribed by the RNA polymerase II into a 
long RNA with hairpin structure, a 5’ 7-methylguanosine cap and a 3’ 
polyadenylated tail (primary miRNA). The pri-miRNA is processed in the nucleus by 
the microprocessor complex (Drosha and DGCR8). The result is a stem-loop 
structure of approximately 70 nt called the pre-miRNA that is exported to the 
cytoplasm by the karyopherin exportin 5 and the Ran-GTP complex (Figure 7). Then 
the pre-miRNA is processed by the enzyme Dicer that generates the miRNA as a 
double stranded RNA of 21-23 nucleotides in length. The two strands are separated 
by helicases, after unwind the active or “guide” strand is loaded into the RNA-
induced silencing complex (RISC) and repress the target mRNA by blocking 
translation or causing transcript degradation. The inactive strand is removed and 
degraded
107
. 
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Figure 7 
The microRNA gene (usually as a polycistronic unit) encodes the primary miRNA transcript (pri-
miRNA) after transcription by RNA polymerase II. This transcript may contain several stem-loop 
structures that are cleaved by the RNA-polymerase type III Drosha to form the pre-miRNA. This step 
requires the presence of the cofactor DGCR8. After being exported from the nucleus the pre-miRNA is 
processed by DICER to form a double strand RNA duplex with the mature miRNA and its 
complementary strand. The RISC complex then recruits the strand with the lowest thermodynamic 
stability at its 5’ end. Indeed both strands (5p and 3p) can have functional effects and be more 
represented in some tissues. The mature miRNAs can be also released to the extracellular space in 
microvesicles or in molecular complexes with the protein Argonaute-2 (Ago) or high-density lipoprotein 
(HDL). DGCR8: DiGeorge syndrome critical region gene 8.  
 
1.2.2 Biological effects of miRNAs 
It has been calculated that miRNAs control up to one third of all human genes
108
. The 
initial observations on the biological role of miRNAs were done in the nematode 
Caenorhabditis elegans
109
, and during the last years several studies have 
demonstrated their critical role in development, cellular differentiation, and the 
maintenance of tissue-specific expression profiles in humans
110
. The mechanisms of 
post-transcriptional regulation by miRNAs are predominantly based on inhibition of 
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translation. Therefore miRNAs are generally regarded as negative regulators of gene 
expression by: a) co-translational protein degradation; b) inhibition of translation 
initiation, and c) premature termination of translation (ribosome drop-off). 
Depending on the degree of complementarity between the miRNA and the target, 
animal miRNAs can also induce cleavage (under perfect duplex), degradation of 
mRNAs or can silence their targets by sequestering the mRNA in discrete 
cytoplasmic foci that exclude the translational machinery 
111
. In recent studies it has 
been observed that miRNAs can also interact with the 5’UTR of the target genes and 
with the coding regions (CDS). Depending on the characteristics of these 
interactions, the miRNAs can increase the translation of a target mRNA by recruiting 
protein complexes to the AU-rich elements on the transcript
112
. This is important 
when evaluating the effects of differentially expressed miRNAs/mRNAs by cross-
pairing. It is worth to mention that given the nature of the complementarity between 
the miRNA and its targets, the biological effect of a miRNA represents the synergy 
of moderate effects on multiple mRNAs. Some miRNAs has been found targeting 
genes that control chromatin structure like PcG genes (EZH2 and Bmi-1), histone 
deacetylases (HDAC1 and HDAC4) and DNMTs (DNMT3A and DNMT3B)
113
. 
Provided that miRNAs not only target mRNA transcripts, but also other non-coding 
RNAs and proteins, the possibilities for miRNA-mediated effects goes beyond post-
transcriptional regulation of mRNA transcripts. Moreover, the miRNA effects may 
act on the same cell that produces them, but if released to the extracellular 
compartment (Figure 7), they can be internalized and regulate biological processes in 
distant cells. 
 
1.2.3 miRNAs as biomarkers and therapeutic targets  
Alterations in the miRNA levels or its regulators have been implicated in almost all 
types of human cancer. Moreover, altered expression of miRNAs has been detected 
in serum and plasma from patients with non-oncological pathologies like active 
tuberculosis, acute myocardial infarction, hepatitis and sepsis
114
. The Human miRNA 
disease database (HMDD) provides a comprehensive tool to explore the relation of 
human diseases and miRNAs. Profiling miRNA expression patterns can classify 
hundreds of tumor samples to their tissue of origin
115
, even in cases of unknown 
primary with an accuracy of 90%
116
. After these initial observations hundreds of 
studies have described the use of miRNAs as potential diagnostic tools, especially in 
cancers, because they can be detected in biofluids like plasma, serum, saliva and 
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urine. The study of miRNAs is of great interest because their potential as non-
invasive biomarkers to help the diagnosis and the prognosis of inflammatory 
diseases, to monitor the response to treatments or to be used in patient stratification 
and individualized medicine. The comparative profiling of miRNAs between patients 
and controls provide the possibility to identify critical miRNAs involved with the 
disease and to develop molecules that can modify their production. Approaches to 
block the production of a specific miRNA include miRNA mimics or anti-miRs by 
using locked nucleic acids (LNA), antagomirs, and miR sponges. Two antagonists 
have reached clinical trials (i.e. miravirsen, MRX34), but most miRNA therapeutics 
are still in preclinical development
117,118
.  
 
1.3 Allergic diseases 
The immune cells are usually beneficial when they participate in protection from 
infections and tumors but can generate several clinical problems when they recognize 
autoantigens or innocuous environmental molecules that are not pathogenic. An 
allergic disease is a clinical condition in which the immune system sustains an 
altered response to molecules that otherwise are tolerated by the majority of the 
population. This inflammatory response induced and maintained by defective 
immuno-regulatory networks, lead to the expansion of inflammatory cell populations 
and to tissue changes that affect organ function and result in clinical symptoms. The 
most common allergic diseases include atopic eczema, allergic asthma, allergic 
rhinoconjuntivitis and food allergy. They usually co-segregate with atopy, an 
intermediate trait defined as the genetic predisposition to produce elevated levels of 
circulating total IgE and/or allergen-specific IgE
119,120
. In the last decades there was a 
dramatic increase in the prevalence of allergic diseases worldwide suggesting that 
something has changed in our modern environments that lead to the dysregulation of 
the immune responses
121
. During the last years, epigenetic modifications started to be 
investigated as an interphase between the environment and the susceptibility to 
allergic diseases
122
; an updated summary of these studies have been recently 
published by Harb et al
123
 and Lockett et al
124
. However, a PubMed search with the 
term “allergy epigenetics” (February 2015) yielded 213 publications, whereof 97 
were review articles. Thus, original research in the field is still very scarce, and 
almost half of all publications represent reviews that typically point out our 
ignorance and need for research. 
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1.3.1 Atopic eczema 
Atopic eczema (AE), also called atopic dermatitis, is a common inflammatory skin 
disease characterized by intense pruritus and xerosis with disease onset in 90% of 
cases before the age of 5 years
125
. The majority of children with AE have a 
spontaneous remission by puberty but at least one third of the patients continue to 
have eczema or relapsing AE in adulthood
126
. By still unknown reasons, the 
prevalence of AE has increased during the last four decades in industrialized 
countries, affecting today 15 to 30% of children and 2 to 10% of adults
14,127
. The 
exact molecular mechanisms that cause AE are largely unknown but a combination 
of skin-barrier defects with alterations in immune regulation is critical for disease 
development. The majority of AE patients present elevated levels of circulating total 
IgE and allergic sensitization to food and environmental allergens. Genetic factors 
are the most prominent determinants for the development of AE, with a concordance 
rate in monozygotic twins ranging from 72 to 86%
128
; however, the susceptibility loci 
identified so far account for 14.4% of AE heritability
129
. Several genes have been 
associated to AE including loss-of-function mutations in the filaggrin gene (FLG) on 
chromosome 1q21.3
130
 and other components of the skin barrier function such as the 
serine peptidase inhibitor, kazal type 5 (SPINK5), and epidermal collagen
131
. Still, 
not all individuals with mutations in skin-related genes develop AE thereby 
additional alterations in the immune system are required to disease inception. Indeed, 
genetic association with the RAD50/IL13 locus and HLA alleles have been detected 
and replicated in European populations
132
, and the most significant susceptibility 
regions as detected by GWAS contain genes that underline the importance of the 
immune dysregulation
133
. 
The histologic features of acute eczematous lesions are epidermal intercellular edema 
and a prominent perivascular infiltrate of lymphocytes, monocytes, dendritic cells, 
mast cells, and few eosinophils in the dermis. In subacute and chronic stages the 
plaques are lichenified and excoriated, the epidermis is thickened and its upper layer 
is hypertrophied
125
. The current knowledge on the pathogenesis of AE indicates that 
a defective skin-barrier (deficiency of ceramides and antimicrobial peptides such as 
cathelicidins, plus defects in structural components in the desmosomes) lead to trans-
epidermal water loss and increased penetration of allergens, microbes and irritants. 
These exposures activates the keratinocytes to produce increased amounts of thymic 
stromal lymphopoietin (TSLP) and the dendritic cells (DC) to produce alarmins (IL-
25, IL-33), chemokines and growth factors that lead to a Th2 polarization of the T 
cell responses in the acute lesions with predominance of IL-4, IL-5, and IL-13 
production
134
. In the chronic lesions there is a predominance of Th1 cells and 
  35 
increased production of interferon gamma, IL-12, IL-5, and granulocyte macrophage 
colony-stimulating factor (GM-CSF). An alternative hypothesis sustain that 
immunological defects lead to IgE mediated allergic sensitization and upon exposure 
to the triggers, the inflammation alters the epithelial barrier, however, early onset 
atopic dermatitis usually emerges in the absence of detectable IgE sensitization
125
.  
Common triggers of flares include heat, sweating, anxiety and infections. Among all 
these exposures, colonization of skin by bacteria and fungi has shown to have 
important roles. Indeed, more than 90% of AE patients have skin colonization by 
Staphylococcus aureus, and even in the absence of signs of infection, the patients 
improve with antibiotic treatment
135
. Malassezia ssp., is a commensal fungus that 
colonizes our skin after birth, but is also associated with several skin diseases among 
those AE
136
. Around 50% of AE patients have detectable specific-IgE sensitization to 
Malassezia allergens and the levels of IgE correlate with disease severity
137,138
. Gene 
expression profiling of skin samples from AE patients with positive patch-test 
reactions to Malassezia revealed the reciprocal differential expression of pro-
inflammatory genes and lipid-metabolism genes that resembles the observations in 
lesional AE skin, supporting the triggering role of Malassezia in the disease
139
. 
The diagnosis of AE is based on clinical criteria and the SCORAD (Scoring atopic 
dermatitis) system is used in research studies to assess and monitor the disease as 
objectively as possible
140
. The skin lesions have a typical age-dependent distribution 
with facial, scalp, and extensor involvement in infants and young children, and 
predominant flexural involvement in older children and adults. Pruritus is a hallmark 
of the disease. Acute lesions are characterized by pruritic papules with erythema, 
excoriations, and serous exudate, whereas chronic AE is characterized by areas of 
lichenification and fibrotic nodules, often accompanied by acute lesions. The disease 
severity varies between patients and from time to time in the same person. Most AE 
patients have mild to moderate disease; but there is a subgroup of patients that 
develop severe symptoms. In those the flare-ups can last several weeks or more, and 
cover many areas of skin. Even worse, some of the patients with severe AE are 
refractory to current available treatments. A link with autoimmune mechanisms has 
been suggested in severe AE by the detection of serum specific IgE antibodies to 
proteins from keratinocytes and endothelial cells
141
. Some of these autoallergens 
have molecular mimicry with microbial compounds such as Malassezia allergens, as 
described for the IgE-mediated and T cell-mediated autoimmunity against 
manganese superoxide dismutase
142
 and thioredoxin
143,144
.  
The first-line treatment of AE includes skin-hydration, topical corticosteroids, and 
topical calcineurin inhibitors (tacrolimus)
145
. Antihistamines are used to treat sleep 
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disturbances and antibiotics and antifungals to treat skin infections. Furthermore, 
allergen-specific immunotherapy has proved to be of use in difficult-to-manage AE 
patients with allergic sensitization
146
. Treatments targeting the immune dysregulation 
include the human monoclonal antibody against the alpha subunit of the IL-4 
receptor (dupilumab) that blocks the functions of IL-4 and IL-13
147
. Up to date, no 
treatment is curative, therefore there is a great need to identify pathogenic events that 
can be modified by primary intervention or can provide clues on how to protect the 
skin-barrier from inflammation and extrinsic triggers. 
1.3.1.1 CLA+ T cells critical players in AE 
Circulating T cells can infiltrate human skin as a mechanism of immunosurveillance. 
They are identified by the expression of the cutaneous lymphocyte-associated antigen 
(CLA), an inducible cell surface glycoprotein that has been extensively characterized 
as skin-homing receptor
148
. In healthy subjects, CLA is expressed by approximately 5 
to 15% of peripheral blood T cells
149
 of the memory subset CD45RO
+
 but not in 
CD45RA
+ 
naïve T cells. Moreover, CLA is detected in almost all T cells infiltrating 
skin in benign and malignant conditions
150
. The ligand of CLA is E-selectin (CD62E) 
which is expressed on the endothelium of postcapillary venules at sites of acute 
inflammation as well as in chronically inflamed skin. The interaction between CLA 
and E-selectin allows the transmigration of CLA
+
 T cells from the peripheral 
circulation to the dermis
151
. Previous studies have shown that AE patients have a 
higher percentage of circulating CLA
+
 T cells compared with HC
152,153
. Also, that the 
T-cell receptor (TCR) repertoire in CLA
+
 cells from AE patients recognize 
superantigens of Staphylococcus aureus, the Malassezia sympodialis allergen Mala s 
13 (with cross-reactivity to human thioredoxin) and mite allergens
152,154-156
.  
The CLA
+
CD45RO
+ 
T cells in the peripheral blood of AE patients induce IgE 
production in B cells and enhance eosinophil survival
157
. They also display features 
of in vivo activation like increased levels of CD25, CD40L and HLA-DR and 
spontaneous release of IL-13
158,159
. Circulating CD4
+
CLA
+
 T cells in patients with 
acute AE produce significantly higher levels of IL-4, IL-13 and tumor necrosis alpha 
compared to patients in the chronic phase of the disease or healthy controls
160
. CLA
+
 
T cells express the chemokine receptors CCR4 and CCR10, and are attracted to skin 
by CCL17, CCL22 and CCL27
161
. These chemokines are produced by keratinocytes, 
vascular endothelial cells, Langerhans DC and inflammatory dendritic epidermal 
cells
162
. After skin homing, the CLA
+
 T cells form dermal infiltrates, secrete 
interferon gamma and make keratinocytes susceptible to apoptosis
163
.   
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Cutaneous inflammation in AE lead to the production of chemokines that allow 
continuous migration of skin-reactive CLA
+
 T cells from the peripheral blood to the 
inflamed lesions (Figure 8). Once in the skin, the CLA
+
 T cells are activated by the 
encounter with their cognate allergens, auto-allergens
164
 and superantigens. A portion 
of the CLA
+
 T cells returns to the blood via the thoracic duct
165
 and display features 
of recent activation and spontaneous production of cytokines. The fact that S. aureus 
superantigens up-regulate the expression of the CLA antigen on T cells
166
 reflects 
that this population is directly influenced by environmental cues of the skin 
microbiome. CLA
+
 T cells infiltrate skin under physiological conditions, but whether 
they harbor intrinsic molecular alterations in patients with AE remains to be 
evaluated.  
 
 
 
Figure 8 
CLA+ T cells (in green) recirculate between peripheral blood and skin. 
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1.3.2 Asthma 
Asthma is a chronic inflammatory disorder in the airways where inflammation leads 
to airway hyper-responsiveness and recurrent episodes of wheezing, breathlessness, 
chest tightness and coughing. However, asthma is a syndrome and an umbrella term 
for many sub-phenotypes thought to originate from different molecular alterations
167
. 
It is a polygenic and multifactorial disease resulting of complex gene-gene and gene-
environment interactions, but the exact initial mechanisms that trigger the 
pathological processes remain unclear. The genetic associations with genes 
implicated with immune pathways and the airway response to environmental 
exposures suggest that leukocytes and bronchial epithelial cells play a major role in 
the origin of this disease. Several initiatives have aimed to classify asthma based on 
the presence of allergic sensitization or atopy (e.g. allergic asthma vs. non-allergic 
asthma) or the response to treatments (e.g. controlled asthma vs. steroid-resistant 
asthma). Besides, great efforts in asthma research are oriented to discover biomarkers 
that can objectively help to better classify the different sub-phenotypes
168
 or help to 
identify groups of patients with particular susceptibilities.  
Asthma has become epidemic reaching 20 to 30% prevalence in UK, Australia, New 
Zealand or Brazil and according to the world health organization (WHO) it is 
estimated to affect 235 million people worldwide. Exacerbating factors include the 
exposure to tobacco smoke, allergens (e.g. from house dust mite, cat, dog, grass, 
pollen, molds, food, etc.), respiratory infections including viruses, exercise and 
hyperventilation, weather changes, sulfur dioxide, air pollution, drugs and additives. 
Early-onset asthma is more likely to be atopic and related to genetic risk factors 
while adult-onset asthma is more related to smoking and triggered by environmental 
exposures
169,170
. The symptoms can fluctuate over time, with periods of remission 
and relapse
171
. In some patients the disease can shift to another phenotype like 
allergic rhinitis or even disappear as “spontaneous cure”. There are gender 
differences in the natural history of asthma; males are more susceptible to the disease 
during early childhood while females develop more symptoms after puberty and are 
prone to have late-onset asthma, some times  in connection to obesity and hormonal 
changes.  
In addition, there are parent-of-origin effects with the antecedent of maternal asthma 
having stronger effects than paternal asthma on the susceptibility to early onset 
phenotypes
170,172
. Studies in mice suggest that epigenetic mechanisms may explain 
the “maternal effect” in asthma, since the splenic CD11c+ DCs of neonates born of 
allergen-sensitized mothers had substantial changes in DNA methylation compared 
to the offspring of non-sensitized mice, and even when they have not been in contact 
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with allergens, the “pro-allergenic DC” can induce allergic inflammation after 
adoptive transfer
173
. 
Nowadays the American Thoraxic Society (ATS) and the Global initiative for asthma 
(GINA) classify asthmatic patients depending on their symptoms and the ability of 
current medications to manage the disease. However, these classifications do not 
consider underlying mechanisms of pathogenesis. Most patients can be controlled by 
current available treatments, but 5 to 10% has the severe-uncontrolled form of the 
disease, non-sensitive to steroids
174,175
. The pharmacological treatment for the control 
of asthma include inhaled corticosteroids (ICS), leukotriene modifiers, long-acting 
inhaled -agonists, and for some patients, systemic steroids, theophylline, cromones 
or the use of monoclonal anti-IgE antibodies. Medications for relieving the 
symptoms include rapid-acting inhaled 2-agonists, systemic steroids and 
anticholinergics. Unfortunately, none of those medications are curative, and allergen-
specific immunotherapy is the only that can modify the course of the disease in some 
patients with allergic sensitization
176
. Therefore, the discoveries of new therapeutical 
targets that can modify the natural history of asthma or prevent its inception are 
highly needed, in combination with diagnostic tools (such as biological markers) that 
allow a better definition of phenotypes and individualized therapy.  
For the phenotype of early-onset asthma (childhood asthma), the current hypothesis 
on the pathogenesis indicates that patients harbor alterations in immune genes and 
defects in the epithelial/mesenchymal trophic unit in the lung
177
. In this scenario, 
intrinsic defects in the bronchial epithelium lead to a dysregulation in cytokine 
production upon exposure to environmental factors like viruses or airborne allergens, 
and this thereby allow extensive infiltration (non-IgE mediated) of immune 
inflammatory cells on the airways
178
. This occurs in the context of type 2 
inflammation and bronchial eosinophilia (which is observed in the majority but not in 
all patients). The chronic stimuli of cytokines and other inflammatory factors 
produced by the epithelium and the cell infiltrate, lead to the differentiation of 
fibroblast to myofibroblast, bronchial smooth cell hyperplasia and the dysregulation 
of other cells in the bronchia, overall leading to bronchial remodeling and the 
perpetuation of the pathological mechanisms
179
. The damage of the epithelium also 
promotes IgE sensitization in individuals with atopic predisposition. The discovery 
of the molecular mechanisms underlying these changes will be helpful for managing 
this still puzzling disorder. 
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1.3.2.1 The asthma susceptibility gene ORMDL3 
In 2007 a GWAS revealed a previously unknown region on chromosome 17q21 
associated with childhood asthma
180
. This finding has been replicated by more than 
20 independent studies conducted in populations with different genetic backgrounds. 
Some of the alleles conferring risk for asthma in the 17q21 locus have been 
associated with the mRNA levels of the underlying genes ORMDL3 (ORMDL 
sphingolipid biosynthesis regulator 3) and GSDMB (gasdermin B). Alleles in the 
17q21 locus may influence the outcome of environmental exposures, for instance, 
Smit et al., described that the effect of bronchiolitis on the predisposition to 
childhood asthma is higher in carriers of the risk genotypes in the 17q21 locus
181
. 
The linkage disequilibrium (LD) within this region is very high and the causative 
gene explaining the association with asthma remains unclear. Epigenetic mechanisms 
were proposed to participate by the observations that asthma-associated SNPs affect 
genotype dependent DNA-protein interactions, nucleosome positioning and insulator 
binding
182
. Also, by studies in human lymphoblastoid cell lines showing that 
methylation levels in GSDMB differ depending on the gene haplotypes
183
. Among 
the five genes narrowed to the asthma-susceptibility region in the 17q21 locus, 
ORMDL3 has been considered the most promising functional candidate. The gene 
spans ~6.5 kb and is transcribed from the minus strand in two known transcript 
variants. The human ORMDL3 belongs to a family of ubiquitously expressed 
transmembrane proteins anchored to the endoplasmic reticulum (ER)
184
, and the 
translated human isoforms contain 153 and 137 amino acids, respectively.  
The connection of ORMDL3 with inflammatory mechanisms was suggested by the 
genetic associations with other chronic inflammatory conditions like inflammatory 
bowel disease
185
, ankylosing spondylitis
186
 and rheumatoid arthritis
187
. Moreover, in 
vitro experiments demonstrated the functional connection of ORMDL3 in 
inflammatory pathways. Breslow et al., described that ORM proteins are critical 
mediators of sphingolipid homeostasis and raised the hypothesis that sphingolipid 
dysregulation contribute to the development of childhood asthma
188
. ORMDL3 binds 
and suppress the serine palmitoyl transferase, a limiting enzyme in de novo synthesis 
of sphingolipids, which induce bronchial hyper-reactivity in murine models of 
asthma. An alternative mechanism on the function of ORMDL3 was presented by 
Cantero-Recasens et al., which revealed that ORMDL3 regulates calcium (Ca
2+
) 
homeostasis in the ER
189
 and facilitates the unfolded protein response
185
. The 
experiments by Carreras-Sureda et al., confirmed that ORMDL3 modify calcium 
signaling in T-cells
190
. These findings are particularly interesting because T cell 
activation rely on depletion of Ca
2+ 
from the ER and the generation of cytoplasmic 
Ca
2+ 
signals that allow the translocation of transcription factors
191
.  
  41 
1.4 Epigenetics and environmental exposures 
Exogenous environmental exposures have been found to change the epigenome at 
DNA methylation, miRNA and histone levels. These exposures include pollutants 
(e.g., metals, polycyclic aromatic hydrocarbons, dioxin-like chemicals, 
polychlorinated biphenyls, phthalates and pesticides), tobacco smoke and 
pharmacological drugs, whereof many have been found to predispose to cancer and 
complex inflammatory diseases
192,193
. The first experimental indications that the 
environment induces changes in DNA methylation were obtained in the agouti 
mouse, in which the feeding of pregnant mothers with a high methyl diet was able to 
change the color of the fur from yellow to wild-type agouti in the pups
194
. Since the 
establishment of DNA methylation marks requires the availability of components 
like methionine, vitamin D, vitamins B6, B12, and folate, nutrition is one of the 
critical environmental exposures shaping the epigenome
195,196
. The hypothesis on the 
developmental origins of health and disease is based on the observations that early 
environmental exposures can induce epigenetic modifications that will influence 
traits later in life, including metabolic responses
197
. Furthermore, air pollution is 
among the best characterized factors associated to DNA methylation changes in 
humans (including particulate matter PM2.5 and PM10), as well as metals including 
arsenic
198
. DNA methylation changes induced by these contaminants have been 
detected in LINE-1 and Alu sequences as well as in coding genes, particularly related 
to the synthesis of nitric oxide and the response to oxidative stress
198
. Drugs like 
hydralazine or procainamide induce SLE in predisposed individuals by mechanisms 
that involve inhibition of DNMT1 and decreased DNMT1 levels, respectively
199
. In 
addition, the exposure of pregnant rats to the endocrine disruptor vinclozolin during 
the period of sex determination induced spermatogenic defects and other 
abnormalities that were even detectable in the F3 and F4 generations
200
.  
In the last years, many other factors have been associated with differences in DNA 
methylation including stressful events
201,202
 and season of conception
203
. The 
exposure to allergens has been associated to changes in DNA methylation and 
miRNA expression in mice models after sensitization and challenge with house dust 
mite extracts
204
. Indeed, mice exposed to a combination of diesel exhaust particles 
and allergens of Aspergillus fumigatus shown the highest levels of total IgE and 
pronounced methylation differences in infg and il4
205
. As I will discuss later in the 
Results and Discussion section, the simultaneous effects of multiple environmental 
exposures on the epigenome are the clues and the challenge when conducting 
epigenetic studies in humans. Among these, the relationship between the commensal 
microbes that reside on the epithelial surfaces and epigenetic changes in human cells 
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is one of the most enigmatic. The gut microbiota can produce metabolites that induce 
epigenetic changes in the colonic epithelium
206
. These observations open the 
possibility that microorganisms on the skin and in the bronchial airways may induce 
epigenetic modifications in cells located in those tissues, but this remains to be 
demonstrated. 
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2 Aims 
The overall aim of this thesis was to investigate the contribution of DNA methylation 
and miRNA expression on leukocyte biology and to identify differences between 
allergic patients and healthy controls that could reveal new insights on 
pathophysiology, disease biomarkers and therapies. 
The specific aims were: 
 
Study I to test the hypothesis that peripheral blood leukocyte populations have 
different DNA methylation signatures associated to cell lineage. 
Study II to compare DNA methylation and miRNA levels in peripheral blood 
lymphocytes of atopic eczema (AE) patients and healthy controls. 
Study III to explore the biological interplay between genotypes, DNA 
methylation and mRNA expression in the asthma susceptibility genes 
GSDMB/ORMDL3 between asthmatic children and healthy controls. 
Study IV to analyze longitudinal trends in DNA methylation levels that occur in 
peripheral blood leukocytes between 3 and 60 months after birth in 
healthy children. 
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3 Materials and Methods 
This section summarizes the samples and methodologies applied to achieve the 
specific aims of this thesis. Detailed information can be found in the papers I to IV. 
Study populations and blood samples 
MALF Study Case-control dataset of adult AE patients and HC from the 
Stockholm area. Six male HC (age 38±13.6 years) provided a 450 
ml blood donation to sort seven leukocyte populations (Paper I  and 
III). Ten AE patients and 10 HC, age and sex-matched, were 
recruited for a cross-sectional comparison of DNA methylation and 
miRNA levels in peripheral blood T cells in connection with 
mRNA expression levels (Paper II). 
BAMSE  Prospective birth-cohort study in Stockholm initiated in 1994 with 
available DNA samples extracted from whole blood at 8 years of 
age for genetic association studies (n=1953) and bisulfite treated 
DNA samples for methylation analyses by EpiTYPER® (n=291), 
and pyrosequencing (n=383), (Paper III).  
Swedish Search Multicenter, nationwide, cross-sectional study on children (age 
12.6±3.9 years) with problematic uncontrolled severe asthma, age-
matched peers with controlled persistent asthma, and healthy 
controls. A subset of 46 children with DNA and RNA samples 
from whole blood, as well as cell counts at time of sampling was 
studied for DNA methylation and mRNA levels in the 17q21 locus 
(Paper III). 
DIPP  Population-based prospective follow-up of Finnish children to 
evaluate risk factors for Type I diabetes. DNA samples were 
extracted from whole blood in ten healthy girls within seven time 
points after birth (3, 6, 12, 24, 36, 48, and 60 months) for 
measuring longitudinal DNA methylation levels (Paper IV). 
Experimental procedures 
Ficoll separation  Starting from a 450 ml blood donation, the blood was diluted 1x in 
sterile PBS. PBMCs and granulocyte fractions were separated by 
density gradient centrifugation using Ficoll-Paque Plus™ (Paper I 
and II). 
Cell sorting Different cell populations from PBMCs and granulocytes were 
labelled with monoclonal antibodies conjugated to microbeads for 
positive and negative selection by  magnetic associated cell sorting 
using commercially available kits from Miltenyi Biotec (Paper I 
and II). 
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Flow cytometry Phenotype of harvested cells after sorting was verified by staining 
with fluorescently labelled antibody panels and expression of cell 
surface markers evaluated in a FACS calibur (Paper I and II). 
DNA extraction  DNA extractions were performed by using commercially available 
kits: QIAmp DNA micro kit (Paper I, II) and FlexiGene kit (Paper 
IV). Samples included in paper III were extracted at the Karolisnka 
Institutet biobank using standard methods. 
RNA extraction  To preserve miRNAs the RNA isolation was performed by the acid 
guanidinium thiocyanate-phenol-chloroform method (Paper II). For 
the mRNA measurements presented in Paper III, RNA was 
previously isolated by using the RiboPure™ Blood extraction kit207. 
Bisulfite treatment Treatment of genomic DNA with bisulfite that convert the 
unmethylated cytosines to uracil but leave the methylated cytosines 
unaffected. For all the samples presented in this thesis we used the 
EZ-96 DNA methylation kit from Zymo Research Corporation 
(Paper I-IV). 
HumanMethylation450 BeadChip Microarray platform from Illumina covering 485 755 CpG sites 
distributed in 99% of RefSeq genes. It detects the methylation level 
at a single base resolution. The 50 bp infinium probe query a C/T 
polymorphism created by bisulfte conversion of unmethylated 
cytosines (Paper I-IV). 
Agilent 8 x 60K array Microarray platform from Agilent technologies with 4774 probes 
covering 2006 human miRNAs (as miRbase v19). The protocol 
requires 100 ng of total RNA as input material and uses Cyanine3-
pCp labelling chemistry and hybridization on microarray slides 
(Paper II).  
STRT sequencing method Genome profilling of transcriptional initiation at the 5’ end of 
transcripts with poly A+ tail. The protocol is a modification of the 
single-cell tagged reverse transcription (STRT) method starting 
from 10 ng of total RNA as input (Paper II). 
Quantitative PCR (qPCR) To investigate gene expression levels of miRNA (Paper II ) and 
mRNAs (Paper II and III); miRNA analysis were done by using the 
miRCURY LNA™ Universal RT microRNA PCR kit (Exiqon). 
For mRNA targets we used validated Taqman probes with beta 2 
microglobulin (B2M) (Paper II) and cyclophilin A (PPIA) as 
endogenous controls (Paper III).  
Sequenom EpiTYPER® Quantitative analysis of DNA methylation levels of targeted 
regions in GSDMB and ORMDL3. Primers were designed in 
Epidesigner and in silico evaluated using MassArray (Paper III). 
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Pyrosequencing DNA sequencing method based on the principle of “sequencing by 
synthesis” and the detection of pyrophosphate release on nucleotide 
incorporation. Since it uses a pre-defined sequence, this method 
was used to measure DNA methylation levels in CpG sites that 
coincide with polymorphisms (CpG site SNPs, Paper III). 
Bioinformatics  
Quantile normalization Non-parametric method to normalize a matrix of probe level 
intensities based on the concept of quantile-quantile plot extended 
to n dimensions. This compensate for systematic technical 
differences between microarrays by forcing the intensities of all 
probes in one standard distribution (Paper I and IV).  
SWAN-normalization Subset-quantile within array normalization for Illumina Infinium 
HumanMethylation450 Bead Chip that allow the Infinium type I 
and type II probes within a single array to be normalized together 
and substantially reduces the differences in beta value (Paper II). 
Batch effect correction Method to combine data from different microarrays and adjust the 
data by the non-biological experimental variation between arrays 
batches and other covariates. The tool ComBat was used (Paper II). 
Statistics 
Moderate t-statistics Ratio of the log2 expression/methylation level to its standard error. 
The standard errors are moderated across genes borrowing 
information from the ensemble of genes and aid with the inference 
about individual genes (Paper II and IV). 
Bayes contrasts  Empirical Bayes shrinkage of the standard errors towards a 
common value (Paper I, II, and IV). 
Causal inference tests Series of conditional association analysis that implement a formal 
statistical hypothesis test, resulting in a p-value. The data include 
genotype, possible causal mediator (e.g. methylation) and one 
outcome of interest (e.g. mRNA expression), see Paper III. 
Multiple testing corrections Re-calculate probabilities obtained from a statistical test which was 
repeated multiple times. The correction by Benjamini-Hochberg 
(also known as q-value) and the Bonferroni correction were used 
(Paper II, III, and IV). 
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4 Results and Discussion 
This section summarizes the main findings of this PhD thesis. Detailed information 
can be found in the papers I to IV. 
4.1 Discovering the genomewide DNA methylation landscapes 
of sorted human blood leukocytes (Paper I) 
The primary goal of this study was to identify differentially methylated CpG sites 
according to cell-lineage in sorted leukocytes from human peripheral blood. A total 
of 60 DNA samples were isolated, including unfractionated whole blood, PBMCs, 
granulocytes and seven sorted cell populations from six adult healthy male blood 
donors. Genomewide DNA methylation levels were measured by the 
HumanMethylation450 BeadChip from Illumina. This study showed, for the first 
time, that the hierarchical clustering of blood leukocytes based on their global DNA 
methylation levels clearly recapitulates their hematopoietic origin, supporting that 
each population of terminally differentiated leukocytes have a particular DNA 
methylation landscape that can discriminate their lineage. Indeed, the DNA 
methylation differences were more prominent among distinct cell types from the 
same individual than within the same cell-type from different donors. The DNA 
methylation marks acquired during hematopoiesis are typical for each leukocyte 
lineage, and as expected, the closer the relation between cells, the lower is the 
number of differentially methylated CpG sites (Figure 9).  
 
Figure 9 
Total numbers of differentially methylated CpG sites between CD4+ T cells vs. cytotoxic T cells (CD8+), 
NK cell (CD56+), B cells (CD19+), monocytes (CD14+), neutrophils (CD16+), and eosinophils (Eos) (left 
panel), and between neutrophils (CD16+) and the other sorted populations (right panel). Black bars 
indicate populations of lymphoid origin and grey bars indicate populations of myeloid origin.        
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It is worth to highlight that CD19
+
 B cells have a very particular DNA methylation 
landscape that separate them from other lymphoid cells on the second principal 
component. The discovery of the differentially methylated CpG sites among these 
sorted blood populations is of great utility to understand which pathways and genes 
may be of functional relevance in terminally differentiated leukocytes under 
physiological conditions. These loci deserve to be further evaluated by in vitro 
experiments to explore their functional effects on leukocyte functions and may be 
also of interest in transdifferentiation experiments.  
Moreover, the results of this study indicated that most of the differentially methylated 
CpG sites between the sorted populations and whole blood (unmethylated and 
methylated) were located in intragenic regions (gene bodies) and were not associated 
to CGI. These observations are in agreement with those by Irizarry et al 
26
 and 
Deaton et al.
32
, and strongly support that the mechanisms implicating DNA 
methylation in cell differentiation involve other genomic regions than promoter-
associated CGI.  
In agreement with previous observations in hematopoietic progenitors
78
 this study 
revealed remarkable differences in the methylation status of the lineage-related CpG 
sites depending if the populations have a lymphoid or myeloid origin. For instance, 
approximately 85% of the CpG sites with significant methylation differences 
between CD16
+
 neutrophils and whole blood were unmethylated, while in CD4
+
 T 
cells and CD8
+ 
T cells the percentages of unmethylated CpG sites with differences 
compared to whole blood were 9.4% and 6.8%, respectively. Conversely, the 
majority of CpG sites with significant differences between CD4
+ 
T cells and whole 
blood were methylated (Figure 10a).  
Our observations on a demethylated genome in human neutrophils compared to 
whole blood, were confirmed by Rönnerblad et al., who described that differentially 
methylated CpG sites generally show decreased methylation during 
granulopoiesis
208
.  Recent studies in sorted populations from healthy individuals 
indicate that hypomethylated regions in neutrophils have effects on gene 
expression
209
. The hypomethylated genome of neutrophils may reflect a lower 
requirement of the DNA methylation machinery in connection with a high cell 
turnover. A more stochastic drift may be expected in neutrophils compared to the 
DNA methylation landscape of lymphocytes. 
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Figure 10 
a. The distribution of the differentially methylated CpG sites between sorted populations and whole 
blood based on their methylations status (unmethylated, marginal or methylated).         
b. Total numbers of differentially methylated CpG sites based on the comparison of M-values between 
whole blood (WB) and T helper cells (CD4+), cytotoxic T cells (CD8+), NK cell (CD56+), B cells 
(CD19+), monocytes (CD14+), neutrophils (CD16+), and eosinophils (Eos).  
 
The discovery of differentially methylated CpG sites according to cell lineage in 
sorted populations of terminally diferentiated blood leukocytes also motivated the 
development of algorithms to correct for differences in cell composition when whole 
blood is used as the source of DNA
210,211
. Especially because for some cell types like 
CD8
+
 T cells or CD19
+
 B cells the number of differentially methylated CpG sites 
compared to whole blood coincide with ~100 000 CpG sites in the assay (Figure 
10b). Our results created awareness in the research community
212
 on the bias that cell 
heterogeneity can cause in DNA methylation studies and the need to sort more 
defined cell types
213
. This is particularly important as many research centers around 
the world have readily available samples to profile DNA methylation levels between 
patients and controls, but most of them had isolated the DNA from whole blood. The 
effect of cell heterogeneity may be even more prominent when studying complex 
inflammatory diseases that change the blood differential cell counts like SLE
214
. The 
Houseman algorithm uses the methylation profiles of lineage specific CpG sites to 
calibrate a regression model that deconvolute the observed methylation levels based 
on the proportion of cell types. However, this approach requires advanced knowledge 
of the dominant cell types in the sample and their methylation profiles to seed the 
algorithm
210
. For some tissues like placenta, adipose or tumor tissues the relevant 
underlying cell types may be unknwon, therefore the field is developing towards 
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reference-free-cell mixture adjustements
215
. Other approaches like FaST-LMM-
EWASher, apply advanced statistical modelling to correct for cell-type composition 
without the need of pure cell profiles; however, it removes large-scale methylation 
changes from the analysis assuming they are caused by cell heterogeneity and 
therefore may not be suitable for studying cancer or methylation differences between 
tissues
216
. In summary this study provided important insights on the DNA 
methylation landscapes that are characteristic of each leukocyte population in human 
blood, and provided a catalog of loci containing differentially methylated CpG sites 
that has been of great value for the development of approaches that correct for 
differential cell composition in genomewide DNA methylation studies. Future 
research should be warranted to elucidate the effects of these differentially 
methylated CpG sites on gene expression and leukocyte functions. 
4.2 Genomewide analysis of DNA methylation and miRNA levels 
in sorted T cells of AE patients (Paper II) 
Studies have reported that differences in DNA methylation
217-219
 and miRNA 
expression
220-222
 might play a role in the pathophysiology of AE. However, no study 
has yet conducted a comparative multi-omic profiling of genomewide DNA 
methylation, miRNA expression and mRNA levels in AE patients and HC. Based on 
the results of Paper I, it became evident that such study requires the use of sorted cell 
populations, at least in a discovery phase. We here tested the hypothesis that 
epigenetic changes associated to AE can be detected in peripheral blood 
lymphocytes. Four populations of T cells (CD4
+
, CD4
+
CD45RA
+
 naïve, CD4
+
CLA
+
 
and CD8
+
) were magnetically sorted from whole blood of 10 AE patients and 10 age-
matched HC. DNA methylation levels were measured using the 
HumanMethylation450 BeadChip. The global expression of approximately 2000 
miRNAs was measured by a commercial microarray platform from Agilent 
Technologies. For the first time, this study revealed that circulating skin-homing 
memory CD4
+
CLA
+
 T cells isolated from AE patients had significant DNA 
methylation differences in 49 CpG sites and differential expression of 16 miRNAs 
compared to HC.  
Among the loci harboring the differentially methylated CpG sites between AE 
patients and HC we found the genes encoding for interleukin 13 (IL13) and the alpha 
chain of the IL-10 receptor (IL10RA). However, for the majority of the CpG sites the 
DNA methylation differences between AE patients and HC were small (about 1.5 
fold). Moreover, none of the genes containing differentially methylated CpG sites 
showed significant differences in mRNA expression; with the exception of IL13 that 
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was found upregulated in the CD4
+
CLA
+
 T cells of AE patients by qPCR but not by 
STRT. The decreased DNA methylation levels in the promoter of IL13 detected in 
this study may be related with the IL-13 dominated Th2 pattern of the CLA
+ 
T cells 
that has been previously reported in AE patients
157,159,160
. Another remarkable finding 
was the identification of differentially methylated CpG sites in several genes 
encoding for enzymes involved in carbohydrate metabolism and with functional 
enrichment in the Golgi membrane. A question that remains to be explored is which 
is the functional outcome (if any) of these small DNA methylation differences and 
their relationships with the disease. The fact that some of these genes are know to be 
co-expressed (like IL10RA and SH2B3) and that many belong to similar biological 
pathways suggest that these DNA methylation differences might not be spurious 
observations. As I mentioned in section 1.3.1.1, the CD4
+
CLA
+
 T lymphocytes 
sorted from blood are memory cells with the possibility to recirculate between the 
skin, the lymph nodes and the peripheral blood, therefore, it is feasible that the DNA 
methylation differences detected in this study, are just the reflection of the activation 
status in the circulating cells of AE patients. Under this hypothesis, the differentially 
methylated CpG sites in the CD4
+
CLA
+
 cells may be remaining markers, a vestige, 
of a series of molecular events that may have already happened within the cells by 
the time they received their priming in the lymph nodes or when contacted by their 
cognate allergens/antigens in the skin.  
This notion is suggested by the fact that the overlap between the differentially 
methylated CpG sites detected in CD4
+
CLA
+ 
T cells and the other 3 lymphocyte 
populations (especially CD4
+
CD45RO
+
 naïve T cells) was very small. Indeed, some 
DNA methylation differences between AE patients and HC may occur earlier in the 
lymphocyte development, as suggested by the detection of three loci that are 
differentially methylated between AE patients and HC but only in CD4
+
CD45
+
 naïve 
T cells; as well as by the detection of one CpG site located in the gene paraoxonase 1 
(PON1) that was significantly more methylated in all four T cell populations of AE 
patients compared to HC. 
The comparative analysis of miRNA expression revealed that only the CD4
+
CLA
+
 T 
cells contained differentially expressed miRNAs between AE patients and HC. Ten 
were up-regulated and six were downregulated in the patients. We confirmed 
significant differential expression between AE patients and HC for miR-21-3p, miR-
130b-3p, miR-150-5p, and miR-1275 by qPCR (although only eigth out of sixteen 
differentially expressed miRNAs were tested). The miRNAs were predicted to target 
some of the differentially methylated genes and some of the differentially expressed 
genes including SOD2 encoding for superoxide dismutase 2 (mitocondrial), PRDX3 
  52 
encoding for peroxiredoxin 3 and HMGB2 encoding for high mobility group box 2. 
Gene ontology (GO) analysis with the combined list of differentially methylated 
genes, miRNA targets and differentially expressed genes revealed a significant 
enrichment in the biological processes of “immune response”, “response to external 
biotic stimulus” and “response to molecules of bacterial origin”. One possible 
interpretation for these observations is that differential methylation, miRNA and 
mRNA expression in the CD4
+
CLA
+
 T cells of AE patients are the outcome of 
environmental cues that are associated to the disease, namely, the exposure of AE 
patients to skin-associated micro-organisms in the context of skin-barrier defects. 
The results of this study revealed that epigenetic marks associated to AE can be 
detected in circulating T cells. Studies on lesional and non-lesional skin biopsies 
obtained from the AE patients and HC are ongoing to visualize the CD4
+
CLA
+
 T cell 
infiltrate and to evaluate if the differentially expressed miRNAs detected in 
circulating cells can be also detected by in situ hybridization. Moreover, the 
differentially expressed miRNAs are being measured in plasma samples from this 
dataset to investigate if they can be detected in circulation. The integrative analyses 
presented in Paper II are just an initial attempt to evaluate the relationship between 
the three data layers but additional pipelines are needed for more comprehensive data 
integration.  
In conclusion, this study revealed for the first time that CD4
+
CLA
+
 T cells of AE 
patients contain cell-specific DNA methylation differences in genes related to Th2 
cytokines, intracellular signaling and carbohydrate metabolism. Moreover, 16 
miRNAs are differentially expressed in CD4
+
CLA
+
 T cells of AE patients compared 
to HC, and predicted to target differentially expressed genes at the mRNA level. The 
miRNA/mRNA regulatory loops are now under study.  
4.3 DNA methylation levels in the GSDMB/ORMDL3 locus 
between asthmatic patients and healthy controls (Paper III) 
The ORMDL3 gene is one of the most replicated susceptibility locus for childhood 
asthma
223
, but its DNA methylation landscape in primary human leukocytes was 
unknown. The aim of this study was to compare the DNA methylation levels of CpG 
sites in ORMDL3, and the nearby gene GSDMB, between asthmatic children and 
healthy controls. The results revealed that some of the most replicated asthma-
associated SNPs (i.e. rs7216389, rs4065275 and rs12603332) coincide with CpG 
sites and given the strong linkage disequilibrium in this locus, the carrier status of the 
polymorphic alleles configures different methylation patterns in these CpG-site 
SNPs. The children carrying the genotype combination confering increased risk for 
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asthma (rs7216389-TT/rs4065275-GG/rs12603332-CC) had 5-6% less methylation 
in two non-polymophic CpG sites located in the 5’UTR of ORMDL3, suggesting that 
asthma-associated CpG-site SNPs do not only affect the methylation status in the site 
they coincide with, but are methQTL for other CpG sites in this region. Although it 
was not possible to point out a causative variant for the genetic association with 
asthma or the association with DNA methylation levels, this phase of the study 
indicated that the 5’UTR of ORMDL3 may contain the genomic interval with 
potential differences in methylation related to the asthma phenotype. It is worth to 
highlight that DNA methylation levels were measured in DNA samples extracted 
from whole blood when the children were 8 years of age, but the majority of 
participants in the patient group had received a diagnosis of asthma by age 4 years. 
The BAMSE birth-cohort was not conceived for this type of epigenetic studies and 
sorted cell populations or cell counts were not available for this dataset. 
Therefore, to obtain a broader view of the DNA methylation landscape of ORMDL3, 
we studied DNA methylation in combination with genotypes and gene expression in 
46 children (15 HC and 31 asthmatics) from the Swedish Search Study. We found 
significant differences in the DNA methylation levels of five CpG sites between 
asthmatic children and healthy controls, that remained significant after adjusting by 
cell counts at the time of blood sampling. Three of these CpG sites also correlated 
with the mRNA levels of ORMDL3. Interestingly, the DNA methylation differences 
were specific between the phenotype of controlled-persistent asthma and HC, but not 
with the phenotype of severe asthma. The DNA methylation differences albeit 
statistically significant after adjustement by cell counts and genotype, were in the 
range of 3 to 6% between patients and controls. Given the small sample size and the 
fact that these measurements were done in whole blood it is feasible that stratification 
during the regression analysis may have resulted in type I error. Nevertheless, we 
found in a parallel sample, analyzed for mRNA expression, that asthmatic patients 
with the phenotype of controlled persistent asthma but not severe asthma have a 
significant up-regulation in the mRNA levels of ORMDL3. These findings in the 
Swedish Search Study strongly indicates that methylation in ORMDL3 could be 
implicated in the pathophysiology of this phenotype, and are in line with previous 
studies suggesting that ORMDL3 is a susceptibility gene that can be predictive of 
persistent wheezing phenotypes
224
. Further studies performed in this dataset by our 
research group, also support that patients with severe uncontrolled asthma may be 
affected by other susceptibility loci
207
.  Furthermore, causal inference tests revealed 
that both, SNPs and the DNA methylation in non-polymorphic CpG sites, have 
independent effects on ORMDL3 mRNA expression, but the effects of the SNPs are 
stronger than CpG sites. Another prominent finding in this study was the discovery 
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of correlation between distant CpG sites that follow a pattern of “linkage” that 
recapitulates the inverse pattern of gene expression at this locus
182
. The finding of 
correlation between CpG sites has been also observed by Liu et al at the genomewide 
level
225
. 
Since the samples used for the comparison between asthmatic children and HC were 
obtained from whole blood, the data obtained in Paper I was used to compare the 
DNA methylation patterns observed in BAMSE and Swedish Search with that in 
sorted cells. Overall, the analysis of sorted populations confirmed that GSDMB is 
mainly methylated and that ORMDL3 contains a CGI that is homogeneously 
unmethylated in all cell types. Moreover, we discovered that CD8
+ 
T cells contain a 
differentially methylated region in the 5’UTR of ORMDL3 that is less methylated 
than in other leukocyte subtypes. Indeed, the two non-polymorphic CpG sites that are 
associated with the carrier status of the risk alleles for asthma are embedded in this 
CD8
+
 T cell differentially methylated region. These findings suggest that DNA 
methylation differences in ORMDL3 might have an impact on T-cells and promote 
lymphocyte driven inflammation. The asthma susceptibility alleles may promote 
increased mRNA expression and DNA methylation changes in the CD8
+
 T cells of 
the carriers, making those individuals more susceptible to a dysregulated 
inflammatory response by CD8
+
 T cells upon viral infections. This finding provides 
insights that could explain the previously observed association between ORMDL3 
with asthma only in the context of personal antecedents of rhinovirus wheezing 
illness
226
, as well as with early-onset phenotypes
227
.  
4.4 On the dynamics of DNA methylation in human blood 
leukocytes between 3 and 60 months after birth (Paper IV) 
Prospective longitudinal analyses on the dynamics of DNA methylation in early 
childhood are essential to identify genes that might be epigenetically modified during 
this period of life, and if disturbed, might contribute to the susceptibility to complex 
inflammatory diseases, including allergic phenotypes. Paper IV was a pilot 
genomewide DNA methylation analysis in whole blood, aiming to elucidate which 
genes have longuitudinal changes in DNA methylation between 3 and 60 months 
after birth in healthy children. A total of 60 serial DNA samples distributed within 
seven time points  (3, 6, 12, 24, 36, 48 and 60 months after birth) were included in 
the analysis. Based on the results of paper I, and to avoid as much as possible the 
confounding effects of differences in cell composition, all the CpG sites showing 
significant differences due to age (n=853) were filtered against a list of CpG sites 
with DNA methylation differences in sorted leukocytes, that serve as cell type 
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classifiers. The present study revealed a catalog of 794 age-modified CpG sites that 
robustly reflect the changes in DNA methylation levels that occur in human blood 
leukocytes within 3 to 60 months after birth. Of these, 330 CpG sites (41.6%) are 
age-methylated and 464 CpG sites (58.4%) are age-demethylated.  
Notably, we found that the genomic location of age-modified CpG sites differ 
depending whether the CpG sites become age-methylated or age-demethylated. Age-
methylated CpG sites are more likely found in gene bodies and within +5 to +50 kb 
downstream of the transcriptional start site (TSS) compared to age-demethylated 
CpG sites, which are more frequently within -5kb and +5 kb from the TSS and are 
associated to promoters and DNAse hypersensitivity sites (DHS). The results of the 
gene ontology analysis made evident that genes containing age-methyated CpG sites 
are significantly over-represented in developmental processes and morphogenesis of 
anatomical structures. This is expected because after lineage choice the peripheral 
blood leukocytes may not require these developmental genes. Still, it was interesting 
that among all the systems, age-methylated CpG sites are significantly over-
represented in genes related to neuronal functions and the formation of neuronal 
structures. Genes harboring age-demethylated CpG sites in blood leukocytes are 
over-represented in immune response genes reflecting the immunological window. 
Indeed, the DNA methylation levels of some genes that have been previously 
associated with chronic inflammatory diseases, like the interferon regulatory factor 5 
(IRF5), the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) 
and the prostaglandin E receptor 4 (PTGER4) are modified during childhood. The 
expression data from the FANTOM5 project
228
 revealed that many of the genes 
containing age-modified CpG sites are expressed in leukocyte populations. These 
findings open new perpectives on the possibility to use environmental exposures to 
modulate the dynamics of DNA methylation on immune genes and to design future 
strategies for primary intervention in susceptible children.  
Moreover, this study revealed for the first time the longitudinal changes in DNA 
methylation that occur in genes encoding chromatin remodelers like SMARCD3 
(SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, 
subfamily D, member 3), in components related to the PcG proteins (including 
CBX7, PHF1, RNF2, KDM2A, KDM2B and JARID2) and histone deacetylases 
(HDAC4). We also identified a number of transcription factors that have longitudinal 
changes in DNA methylation during childhood and may be of relevance for the 
maturation of the immune response 
229
. The results of this study suggest that age-
related changes in DNA methylation during this period of life may not be only due to 
a stochastic drift but rather correspond to a program with potential relevance for 
  56 
leukocyte biology. Moreover, the 794 age-modified CpG sites identified in this study 
may be very useful in developing tools to correct for age effects when performing 
DNA methylation studies in children.  
4.5 Methodological considerations 
The studies included in this doctoral thesis contain several methodological 
limitations that are discussed in each of the papers (I-IV). In the following lines I will 
comment their potential impact when interpreting the results and the scope of this 
work.  
First, the number of samples included in the studies was small. Nevertheless, a 
sample size may be appropriate or not depending on the research question and the 
effect sizes. A total sample size of sixty samples from six healthy male individuals 
was enough for studying cell-lineage specific DNA methylation levels (Paper I). In 
this case, DNA methylation differences associated to leukocyte lineage differed more 
between cell types than between individuals. The clustering of cell types based on 
DNA methylation was later validated in 20 independent individuals in an ongoing 
study (data not shown). In Paper II and Paper III the aim was to compare DNA 
methylation levels between groups of patients and controls. In this case, it should be 
noted that the sample size was underpowered to draw convincing results, especially 
because the observed differences between groups are typically small. Due to the 
small number of participants, it is not possible to rule out type II error by lack of 
statistical power. Several logistic and methodological reasons allowed us only to 
study these numbers of individuals; nevertheless, the methodological design included 
a careful selection of participants based on the strategy of the extreme phenotypes, as 
an attempt to compensate the small sample size with including more homogeneous 
groups of patients.  
In paper IV, a total of sixty samples were analyzed and this might have limited the 
power to detect age-associated changes in methylation. This is to our knowledge, 
however, the largest number of repeated DNA samples from the same individuals 
analyzed ever for longitudinal changes in genomewide DNA methylation during 
childhood. Thus, the availability of measurements over many time points 
compensates by the small number of children. In combination with a very astringent 
statistical model, the small sample size could explain why the list of age-modified 
CpG sites was shorter in this study compared to previous reports
230
. We replicated 
previously known age-modified loci in this dataset, like the differences in the AT 
rich interactive domain 3A (ARID3A) and discovered many new loci that require 
further verification. Given the small sample size and to avoid the confounding effects 
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that gender differences may introduce in the DNA methylation measurements, it was 
decided to include only males in Paper I and II and only girls in Paper IV. Second, it 
may appear counterintuitive based on the results of Paper I, but DNA extracted from 
whole blood was used in Paper III to compare DNA methylation between asthmatic 
children and controls, and in Paper IV to evaluate longitudinal changes in DNA 
methylation. The selection of those samples was based on availability in the 
framework of birth cohorts that were not originally intended for epigenetic studies 
but that provide the unique opportunity to use DNA and extensive clinical records. I 
think this is a common limitation for many ongoing studies worldwide that are using 
datasets from the GWAS era to study epigenetics. Adjustments by cell counts (Paper 
III) or verification of the differentially methylated CpG sites in the catalog of cell-
lineage CpG sites (Paper III and Paper IV) were used as strategies to avoid  
confounding. It cannot be ruled out that some of the observations resulted of type I 
error by compositional differences in blood. This is particularly the case for the 
comparisons performed in BAMSE (Paper III) and in DIPP (Paper IV).   
Another source of variation that must be discussed belongs to the methodologies that 
were implemented to access DNA methylation, miRNA expression and other 
biological readouts. DNA methylation analysis can be performed by numerous 
methods including methyl binding proteins, restriction enzymes or bisulfite 
sequencing. For genomewide screenings, the Human Methylation450 BeadChip 
from Illumina was the most robust and comprehensive microarray technology by the 
time that these analyses were done. However, even though it contains CpG sites 
distributed in 99% of the genes described in RefSeq, it is biased towards a higher 
number of CpG sites in the proximities of promoter-associated CGI. This may affect 
the possibilities to detect relevant DNA methylation differences in intragenic regions, 
especially when comparing methylation between cases and controls. Provided that 
there is a high degree of correlation between CpG sites spanning within the same 
regions, most probably the sites included in the array have allowed fishing regional 
signals. During the last years, a number of methods were evolving for analyzing 
450K data in terms of pre-processing the raw data, normalization and analysis on 
differential methylation
231
. The different approaches implemented in Papers I-IV 
reflect some of these changes.  
A substantial amount of work was invested in the technical validation of 450K 
measurements by other methods like EpiTYPER
®
 and pyrosequencing, and many of 
the observations were consistent. In our hands, EpiTYPER
®
 proved to have a very 
small standard deviation between duplicates in most of the CpG sites. However, it 
should be noted that the margin of technical variation for these methods (especially 
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pyrosequencing) may encompass the observed DNA methylation differences 
between cases and controls. The bisulfite treatment of DNA samples could also 
introduced sources of bias. In paper II, miRNA levels were measured by a 
microarray platform from Agilent Technologies. This was found to have the most 
consistent performance in miRNA detection over qPCR, sequencing, and other 
microarray platforms
232
. These results were consistent and some of the differentially 
expressed miRNA indeed validated by qPCR. The samples used for miRNA analysis 
were extracted using the acid guanidinium thiocyanate-phenol-chloroform method 
(without columns) and this procedure resulted to be very effective to obtain 
consistent amounts of miRNAs with broader representation of miRNAs species. 
Moreover, the extractions were done from normalized cell numbers, with a minimum 
of 2.5 million cells as input; therefore it is very unlikely that the miRNA analysis 
have been affected by low input cell numbers. Furthermore, the mRNA analyses 
were done using a modified STRT method which by sequencing the first 37 bp of the 
5’-end of polyA-tailed RNAs in 10 ng total RNA provides an indication of 
transcription start sites and expression levels
233
. In contrast to microarray 
technologies, this sequencing protocol has a broader dynamic range, higher 
sensitivity and is less susceptible to cross-hybridizing molecules. Some of the mRNA 
expression differences between AE-patients and HC by STRT were validated by 
qPCR (Paper II). 
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5 Concluding remarks and future perspectives 
Beyond the epigenetic mechanisms discussed in this thesis (i.e. DNA methylation 
and miRNAs), it becomes evident that we are just at the very beginning. The 
evidence accumulated until now supports that the complexity of the genome involves 
many other layers of regulation, that being studied under the current reductionist 
approaches can only provide a limited view of the cell biology. The technological 
advances in the coming years will be oriented to develop methodologies that allow 
the simultaneous analysis of diverse layers of epigenetic regulation with deeper 
resolution, and the integration of their biological readouts taking into account 
emergent processes. The genome research will be focused on more global 
mechanisms that can explain the unsolved questions by the conventional view that 
we have of the genes and their close regulators. This is especially important when the 
profiling of patients with complex inflammatory diseases and healthy controls 
repeatedly revealed small epigenetic differences between groups, within diverse loci, 
but without obvious biological readouts. Hopefully new analytical models will help 
to disentangle their combined effects under the principles of systemic biology. In 
addition, it can be anticipated that many more epigenetic mechanisms are to be 
discovered, as well as the functions of other chemical modifications on cytosines 
(like 5-hydroxymethilcytosine) and the role of the “transcribed-non-translated” 
genome.  
The discoveries generated during the past four years in the framework of this thesis 
opened new theoretical insights on the mechanisms involved in leukocyte physiology 
and the pathogenesis of allergic diseases. One of the main conclusions is that the 
epigenetic modifications may not be the determining events leading to altered cell 
phenotypes (or “causative”), but rather components in a series of events that 
configure cell physiology and its altered status in the presence of pathology. The 
environment, assumed as the global network of signals that are sensed by cells, 
induce changes in the epigenetic landscape and is probably the key behind the 
modest differences that we detect in our samples. Future translational studies aiming 
to elucidate mechanisms in multifactorial diseases like asthma or AE should focus on 
disentangle the genomic changes that follow the interactions between the immune 
cells and their environment, to unravel the exposome. If we consider the epigenetic 
changes as a metabolic outcome of environmental effects, there is a unique 
opportunity to use them as objective measurements of more global processes.  
Moreover, the implementation of longitudinal studies with extensive sampling before 
and after disease inception will be crucial to understand at the molecular level when 
  60 
do human complex inflammatory diseases start, because once the symptoms are 
established it is very difficult to differentiate the epigenetic mechanisms that occur at 
early stages on the pathogenesis from those resulting of ongoing inflammation or 
treatments. In this sense, the evaluation of in utero exposures and even the sampling 
of the parents during pre-conception and pregnancy must be considered. Ongoing 
studies in the Assessment of Lifestyle and Allergic Disease During INfancy 
(ALADDIN) birth-cohort, including samples during pregnancy and delivery are 
targeting these questions
234
. But, how far in the developmental history of an 
individual can we trace an epigenetic mark? Lamarck and others
235,236
 proposed the 
transgenerational inheritance of acquired characters. Only the future will reveal if 
some of the epigenetic marks involved in the pathogenesis of allergic inflammation 
can remain after the two steps of genome resetting and be transmitted by meiosis 
from parents to siblings.  
Overall, our results support a transformation in the current view of the genome, 
traditionally observed as a static entity only modified by sequence variations, and 
studied with analytical tools that were developed based on the mechanisms leading to 
monogenic diseases. If we imagine the environment and the cell as a continuum with 
the epigenetic modifications as an interphase, a challenging question to be sorted in 
the future is: how to distinguish the basal noise from those epigenetic changes that 
result in changes of the cell phenotype?  Or from epigenetic changes that contribute 
to human complex diseases? 
The concepts discussed in this thesis, only known by experts in cell biology until few 
years ago, have permeated several disciplines of the biomedical sciences and created 
an impact in the strategies to study complex diseases. Provided that we and others 
have detected epigenetic modifications associated to asthma and AE, there are 
possibilities to test their use as biomarkers of sub-clinical phenotypes or be targeted 
by novel therapies. The discovery of significant DNA methylation differences in the 
subgroup of children with controlled persistent asthma but not in those with severe 
asthma (Paper III), suggested that molecules like ORMDL3 may be implicated in the 
pathogenesis of sub-phenotypes and therefore a critical candidate for personalized 
medicine. We also found several genes belonging to common biological pathways 
that harbor DNA methylation differences in patients with AE. The following step 
will be to identify critical, non-redundant bottlenecks within these pathways to 
design novel specific therapies or disease preventing strategies. We also found that 
DNA methylation in several immune genes and chromatin remodelers is dynamic 
within childhood (Paper IV). More studies are needed to elucidate if the disease-
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associated epigenetic changes can be modulated by environmental exposures and if, 
hopefully, are amenable to be modified by primary interventions.  
Last but not least, I would like to summarize some practicalities to consider when 
designing future epigenetic studies: 
a) The ideal strategy to perform epigenetic studies should be to obtain purified cells 
from the organs affected by the disease under study. For instance, to investigate 
epigenetic mechanisms in AE, the profiling on sorted blood leukocytes can be 
correlated with the study of epigenetic modifications in skin biopsies of lesional and 
non lesional tissues. Studies investigating epigenetic modifications associated with 
asthma should assess the cellular elements in the BAL as well as bronchial biopsies. 
For instance, there is evidence that some epigenetic differences occurring in 
asthmatic patients can only be detected in cells from the lungs but not in PBMCs
237
. 
b) Even if the affected tissues are available, it should be kept in mind that a biopsy 
usually contains different cell types and by studying such tissue there is always the 
possibility that the signals get diluted between affected and non-affected cells. 
Therefore it is essential to apply appropriate methodologies to control for tissue 
heterogeneity. This is especially important when the disease-associated epigenetic 
differences are more likely to be restricted to particular cell types as it was found in 
Paper II. 
c) The use of whole blood as the source of DNA should be carefully considered and 
must take into account the characteristics of the loci under study. Similarly as for 
tissue-derived samples, it is necessary to use appropriate algorithms to correct by cell 
composition when using DNA samples extracted from whole blood
210,211,213,216
.  
d) Some of the limitations imposed by the study of bulk of cells can be solved in the 
future by profiling of epigenetic signatures at the single cell level
238
.  
e) It is necessary to plan and collect the samples by using reagents and appropriate 
conservation and storage procedures that allow preserving the different epigenetic 
modifications in clinical settings. This is especially relevant for transitory or less 
stable marks as histone modifications or modifications in DNA bases apart of 5-
methylcytosine. 
f) It is very important to study primary cells, meaning that samples should be 
obtained directly from the individuals under study. The procedures to culture or to 
immortalize the cells alter their epigenetic profiles to a point in which they no longer 
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resemble the primary cell type and therefore are not a reliable source of DNA for 
epigenetic studies
239
  
g) Since the epigenetic modifications are extremely susceptible of being modified by 
environmental factors, for instance, season of sample collection
72,203
 all epigenetic 
studies should be conducted with appropriate pairing by age, gender, ethnicity and 
sociodemographic factors between cases and controls. It should be considered that 
optimal population based-studies on epigenetic variation may require new analytical 
strategies that differ to those implemented in genetic epidemiology
240
. 
Nowadays, several consortia like the roadmap epigenomics project 
(http://www.roadmapepigenomics.org/) and the international human epigenome 
consortium (http://www.ihec-epigenomes.org/) are mapping human epigenomes for 
normal and diseased cell types, thus many new discoveries regarding the role of 
DNA methylation in leukocyte function are to come within the next years.  
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6 Populärvetenskaplig sammanfattning* 
Allergiska sjukdomar såsom atopiskt eksem och astma är kroniska, inflammatoriska 
sjukdomar där balansen mellan de mekanismer som reglerar immunsystemet 
påverkats samtidigt som det finns defekter i målorganen såsom huden vid atopiskt 
eksem eller epitelet och den glatta muskulaturen i luftrören vid astma. Ärftlighet i 
form av variationer i DNA-sekvensen i kombination med exponering för 
miljöfaktorer kan utlösa eller bidra till sjukdomen. Allergen från t.ex. björkpollen 
och jordnötter, är exempel på utlösande miljöfaktorer och virussjukdomar i lungorna 
kan vara bidragande. Interaktion mellan ärftlighet och miljö kan ge upphov till 
förändringar hos celler och molekyler som vi ännu inte förstår. Dessa förändringar 
kan skada cellens funktion och bidra till utveckling av allergiska symptom. Under de 
senaste fyrtio åren har förekomsten av allergiska sjukdomar ökat dramatiskt. Detta 
kan tyda på  förändringar i livsstil och våra moderna miljöer som därmed påverkar 
balansen i vårt immunförsvar. Förbättrad hygien har medfört en mindre exponering 
för mikroorganismer och parasiter samt en minskning av den biologiska mångfalden. 
Några forskare menar att dessa miljöförändringar påverkar cellernas funktion i 
immunförsvaret möjligen via epigenetiska mekanismer. Exempel på epigenetiska 
förändringar är modifiering av DNA och kromatin. Dessa modifieringar kan påverka 
uttrycket av gener utan att förändra den underliggande DNA-sekvensen och överförs 
från cell till cell när dessa delas.  
Målsättningen med denna avhandling har varit att studera eventuella skillnader i 
epigenetiska faktorer mellan allergiska patienter och friska personer samt DNA-
metyleringsmönster i de olika vita blodkropparna för att öka kunskapen om 
sjukdomsmekanismer och därmed finna nya strategier för prevention och behandling. 
I studie I fann vi att varje enskild studerad population av vita blodceller har 
karaktäristiska mönster av DNA-metylering som kan relateras till cellhärkomst. 
Lymfoida celler är mer metylerade än de myeloida. Studien visar att när man studerar 
DNA metylering i blodprover utan att isolera specifika celltyper kan resultaten 
påverkas mer av de cellspecifika skillnaderna i metyleringsmönster snarare än den 
sjukdom man studerar.  
I studie II fann vi att en variant av T-celler, så kallade CD4
+
CLA
+
, skiljer sig 
epigenetiskt mellan patienter med atopiskt eksem och friska kontrollpersoner. 
Faktorerna inkluderade DNA-metylering och uttrycket av 16 mikroRNA. De gener 
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som var berörda av dessa skillnader är nu identifierade och kan i framtiden tjäna som 
nya markörer för att diagnostisera atopiskt eksem eller agera mål för nya 
behandlingar. 
I studie III analyserade vi effekten av ärftliga variationer i DNA-sekvensen samt 
förändringar i DNA-metyleringen i kromosomregionen där bl a generna 
GSDMB/ORMDL3 är lokaliserade, en region som kopplats till ökad risk för astma. 
Vi fann skillnader i DNA-metylering hos barn med lindrig, kontrollerad, ihållande 
astma jämfört med friska barn. De metyleringsnivåer i ORMDL3 som visade skillnad 
hos de astmatiska barnen jämfördes med genuttrycket för generna i regionen. Genen 
som kodar för ORMDL3 befanns mindre metylerad i cytotoxiska CD8
+
 T-celler som 
skyddar oss mot virusinfektioner. Tillsammans indikerar dessa fynd att skillnader i 
DNA-metylering i genen som kodar för ORMDL3 skulle kunna bidra till de 
mekanismer som gör att barn i tidig ålder lättare utvecklar astma efter 
virusinfektioner. 
Allergiska sjukdomar kan både uppstå och försvinna under barndomen alternativt 
kvarstå upp i vuxen ålder. I studie IV studerade vi DNA-metyleringsnivåerna i vita 
blodkroppar över tid för att finna genregioner som uppvisar förändringar i tidig ålder, 
mellan 3 och 60 månader efter ett friskt barns födelse. Vi fann 330 DNA regioner 
som visar ökad metylering under denna tidsperiod och 464 regioner där metyleringen 
minskar. De gener som finns i dessa regioner påverkar bl.a. mognaden av 
immunsystemet och reglerar genomet. 
Sammanfattningsvis visar dessa studier att DNA-metyleringsmönster skiljer sig 
mellan olika typer av vita blodkroppar och att det finns regioner i DNA som erhåller 
förändrade metyleringsnivåer under barndomen hos friska barn. Vi har också visat 
epigenetiska skillnader mellan friska personer och allergiska patienter med atopiskt 
eksem och barn med astma. Dessa fynd ger oss ledtrådar för att kunna utveckla nya 
och bättre biomarkörer och behandlingar för dessa sjukdomar. 
 
*Översatt från spanska av Kesrtin Lagercrantz. Redigerad av Lovisa E. Reinius, Annika Scheynius och 
Cilla Söderhäll. 
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7 Resumen de divulgación científica  
Las enfermedades alérgicas como el eczema atópico (EA) y el asma son 
enfermedades inflamatorias crónicas en las cuales los pacientes sufren de defectos en 
los mecanismos que regulan el sistema inmune, y al mismo tiempo, tienen defectos 
en células relacionadas con los organos afectados por la enfermedad, por ejemplo la 
piel en el caso del EA o células del epitelio o el musculo liso de los bronquios en el 
caso del asma. En la aparición de estas enfermedades participan, por una parte, la 
susceptibilidad genética que esta codificada por variaciones en la secuencia del ADN 
y por otra la exposición a factores ambientales que desencadenan la enfermedad, por 
ejemplo, la exposición a altas concentraciones de alergenos, infecciones virales, el 
contacto con el humo de cigarrillo, etc. De las interacciones entre los genes y el 
ambiente resultan alteraciones moleculares que dañan el funcionamiento celular y 
finalmente llevan a los síntomas alérgicos, los cuales todavía no están bien 
comprendidos. Durante las últimas cuatro décadas ocurrió un aumento en la 
prevalencia de enfermedades alérgicas en el mundo. Muchos factores se han 
asociado con este fenomeno, por ejemplo la contaminación ambiental, los cambios 
en el estilo de vida, el mejoramiento de la higiene que ha llevado a una menor 
exposición a bacterias y parásitos y la reducción de la biodiversidad. Algunas 
hipotesis sugieren que esos cambios ambientales afectan las funciones de las células 
del sistema inmune como los linfocitos, al parecer mediante mecanismos 
epigeneticos. Estos son modificaciones químicas en el ADN y la cromatina que 
pueden cambiar la expressión de los genes sin cambiar la secuencia de ADN y que se 
transmiten de célula a célula cuando estas se dividen. Hay evidencias para pensar que 
las modificaciones epigeneticas ayudan a entender las alteraciones genomicas que 
llevan a las enfermedades alérgicas e inflamatorias. El objetivo general de esta tesis 
doctoral fue elucidar las diferencias en la metilación del ADN que se relacionan con 
el linaje celular y la edad en linfocitos de sangre periferica; además comparar los 
niveles de metilación del ADN y de expression de microRNAs entre personas sanas 
y pacientes alérgicos. 
En el estudio I se descubrió que cada población de leucocitos circulantes tiene 
patrones caracteristicos en la metilación del ADN relacionados con su linaje celular.  
Además, que las celulas de origen linfoide están más metiladas de las células de 
origen mieloide. Este estudio tambien reveló que cuando se hacen estudios de 
metilación usando muestras de sangre completa los resultados pueden afectarse por 
diferencias en la proporcion de las diferentes células.  
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En el estudio II se descubrió que una población de linfocitos T llamada CD4
+
CLA
+
 
contiene diferencias significativas entre pacientes con eczema atópico y controles 
sanos, tanto en la metilación del ADN como en la expression de 16 microRNAs. Se 
identificaron los genes afectados por esas diferencias y algunos de ellos pudieran ser 
investigados en el futuro como nuevos marcadores de la enfermedad o candidatos 
para ser bloqueados por nuevos tratamientos.  
En el estudio III se analizó el efecto de las variaciones en la secuencia de ADN que 
predisponen al asma y los cambios en la metilación del ADN en una región que 
confiere susceptibilidad al asma denominada GSDMB/ORMDL3. Se encontraron 
diferencias significativas en la metilación entre niños con asma controlada persistente 
y los controles sanos. Los niveles de metilación en los sitios CpG con diferencias en 
los niños asmaticos se correlacionaron con los niveles de expresión del gen 
ORMDL3. En este estudio tambien descubrimos que el gen ORMDL3 esta menos 
metilado en los linfocitos citotoxicos CD8
+
 generalmente asociados con la protección 
contra las infecciones virales. Estos hallazgos sugieren que las diferencias de 
metilación en el gen ORMDL3 afectan principalmente este tipo celular, siendo uno 
uno de los mecanismos que predisponen al asma de inicio muy temprano e inducida 
por infecciones virales. 
Una caracteristica interesante de las enfermedades alérgicas es que pueden aparecer y 
luego desaparecer durante la infancia o seguir un curso crónico. En el estudio IV se 
realizó un análisis preliminar de los niveles de metilación global en leucocitos 
circulantes con el fin de identificar los genes que tienen cambios en la metilación 
entre los 3 y los 60 meses después del nacimiento en niños sanos. Se encontraron 330 
sitios CpG que aumentan su metilación durante ese periodo y 464 sitios CpG que la 
tienen disminuida. Los genes que contienen esos cambios estan relacionados con la 
maduración del sistema inmune y con muchas moleculas que remodelan el genoma.  
En resumen, los estudios que componen esta tesis doctoral llevaron al 
descubrimiento de marcas en la metilación del ADN particulares en cada tipo de 
leucocitos en sangre periferica y además a la identificación de un catalogo de genes 
que cambian su metilación durante la infancia en las personas sanas. Además, 
revelaron diferencias entre personas sanas y pacientes alérgicos. Esos hallazgos 
proporcionan nuevas pistas para el desarrollo de ensayos que sirvan como 
biomarcadores de esas enfermedades asi como para el desarrollo de nuevos 
tratamientos.    
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